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Human immunodeficiency virus-1 (HIV-1) is a lentivirus responsible for development of AIDS.  
In addition to typical retroviral proteins (Gag, Pol and Env), primate lentiviruses like HIV-1 
encode two regulatory (Tat and Rev) and four accessory proteins (Vif, Vpu, Vpr and Nef). The 
HIV-1 accessory factor Nef is essential for high-titer viral replication and AIDS progression.  
Nef function requires interaction with many host cell proteins, including specific members of the 
Src kinase family.  In this dissertation project, I explored whether Src-family kinase (SFK) 
activation is a conserved property of nef alleles from a wide range of primary HIV-1 isolates and 
its sensitivity to selective pharmacological inhibitors.  Representative Nef proteins from the 
major HIV-1 subtypes A1, A2, B, C, F1, F2, G, H, J and K strongly activated Hck and Lyn as 
well as c-Src to a lesser extent, demonstrating for the first time that SFK activation is a highly 
conserved property of primary M-group HIV-1 Nef isolates.  Moreover, patient-derived Nef 
proteins also strongly activated Hck. Recently, our group identified 4-amino 
diphenylfuranopyrimidines (DFPs) and diphenylpyrazolyldiazene (PPD-B9) compounds that 
selectively inhibit Nef-dependent SFK activation as well as HIV replication. To determine 
whether these novel compounds exhibit broad-spectrum Nef-dependent antiretroviral activity 
against HIV-1, I first constructed chimeric forms of the viral strain NL4-3 expressing the same 
10 primary nef alleles. The infectivity and replication of these Nef chimeras was 
indistinguishable from that of wild-type in three distinct cell lines (MT2, U87MG and CEM-T4). 
Importantly, the 4-aminopropanol and 4-aminobutanol derivatives of DFP as well as PPD-B9 
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potently inhibited the replication of all chimeric forms of HIV-1 in both U87MG and CEM-T4 
cells in a Nef-dependent manner.  The effects of these compounds against HIV replication 
correlated with inhibition of Nef-dependent activation of endogenous SFKs. My results 
demonstrate that the activation of Hck, Lyn and c-Src by Nef is highly conserved among all 
major clades of HIV-1 and that selective targeting of this pathway uniformly inhibits HIV-1 
replication. My results have strong public health significance for developing therapeutics against 
current drug resistant variants of HIV-1. 
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1.0  INTRODUCTION 
Human immunodeficiency virus-1 (HIV-1) is an enveloped RNA virus belonging to the genus 
Lentivirus of the Retroviridae family and is the causative agent responsible for acquired immune 
deficiency syndrome (AIDS). After infection, the HIV-1 RNA genome is reverse transcribed to 
DNA and can integrate into host cell chromosome, which in turn can become a continuous 
source of viral progeny throughout the life of host cell (61,271). There are three major groups of 
HIV-1 sequences: M (major), O (outliers) and N (non M, non O).  Among these, the HIV-1 M 
group is diversified into nine subtypes/clades (A to K) as well as several circulating recombinant 
forms (CRF) and are mainly responsible for global AIDS pandemic (174). 
The first report of a mysterious disorder affecting five gay men in California occurred in 
1981, yet there is still no curative treatment or vaccine for AIDS (1). These 30 years of 
worldwide epidemic of AIDS has caused the death of more than 25 million people. It is very 
difficult to develop a globally effective vaccine for HIV-1/AIDS due high variability of the HIV 
genome as well as its high mutation rate. Several different vaccine approaches have been tried 
but still there is no effective vaccine available. The development of highly active anti-retroviral 
therapy (HAART) during the mid-1990’s substantially reduced the mortality associated with 
HIV/AIDS, effectively turning the disease from a death sentence into a chronic disease for those 
with access to antiretroviral drugs. However, as with the vaccine approach, the high mutation 
rate of HIV-1 continues to make HAART therapy less effective in controlling new infections 
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over time. Most anti-retroviral drugs currently used for AIDS treatment target HIV-1 proteins 
(e.g., reverse transcriptase, protease) which selects for drug resistance. This reality underscores 
the strong need for developing new drugs by targeting essential host-viral protein interactions in 
the hope of reducing the chances of developing drug resistant mutant. Our group is actively 
pursuing this approach, and has discovered several new classes of inhibitors of HIV-1 replication 
that target the interaction of HIV-1 Nef with the host cell kinase, Hck.  
As these newly discovered anti-retroviral compounds are potential leads for AIDS 
therapeutics, the present study evaluated their broad-specificity against all major clades of HIV-
1. In the course of these studies, we have shown for the first time that the activation of a subset 
of Src family kinases (SFKs) is a highly conserved property among all major clades of HIV-1 
Nef. Then we showed that these newly discovered compounds are broadly active against Hck 
following activation by each of these Nef variants. Moreover, we showed for first time that 
targeting this cell signaling pathway broadly inhibited HIV-1 replication in a Nef-dependent 
manner in two different host cell systems.  These discoveries set the stage for further 
development of these compounds as a new approach to antiretroviral therapy. 
  3 
1.1 HUMAN IMMUNODEFICEINCY VIRUS 
The Human Immunodeficiency Virus (HIV) belongs to the genus lentivirus (slow growing virus) 
of the Retroviridae family and is the causative agent of Acquired Immune Deficiency Syndrome 
(AIDS) (61,271). The HIV virion consists of a diploid genome containing two copies of positive-
sense 5’ capped RNA enclosed within a capsid and a lipid envelope. After docking on host cells 
by binding of HIV envelope proteins to host cell surface receptor CD4 as a primary receptor and 
either CXCR4 or CCR5 as a co-receptor; the virus enters into the cells.  The choice of co-
receptor determines the tropism of HIV-1. The macrophage tropic (M-tropic) strains also known 
as non-syncitia-inducing strains (NSI) enter by binding to the β-chemokine receptor CCR5 while 
the T cell tropic (T-tropic) strains also known as syncitia-inducing strains (SI) enter by binding 
to α-chemokine receptor CXCR4. The dual-tropic viruses are able to use both CCR5 and CXCR4 
as co-receptors for entry into host cells (49,59). Following infection, viral proteins and the RNA 
genome are released into the cytoplasm. The single-stranded HIV RNA genome undergoes 
reverse transcription into double-stranded DNA by the viral reverse transcriptase, followed by 
transport into the nucleus where it integrates into host chromosomal DNA. Upon availability of 
specific host cell transcription factors, the viral genome is transcribed to produce various 
structural and regulatory proteins as well as full length copies of the RNA genome for packaging. 
Then new virions are assembled at the cellular membrane and released from the cell via budding 
[reviewed in (44,60,158)]. 
HIV-1 is mainly transmitted through homosexual or heterosexual intercourse, transfusion 
of infectious blood and from mother-to-child, but not every exposure leads to infection and not 
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every infection progresses to AIDS [reviewed in (84)]. Depending upon virus and host genetics, 
HIV infection eventually causes AIDS which is characterized by a drop in CD4
+
 T cell counts 
and susceptibility to opportunistic infections such as Pneumocystis pneumonia, esophageal 
candidiasis, or toxoplasmosis, as well as certain AIDS-associated cancers, such as non-Hodgkins 
lymphoma and Kaposi’s sarcoma [reviewed in (158,182,235,271)].  
Although 30 years have passed since the first report of AIDS by the CDC, no curative 
treatment or vaccine has been developed. Though several candidate vaccines have been 
evaluated in clinical trials, the high rate of HIV mutation, variations in the host immune response 
and the development of quasispecies within the same patient make it challenging to develop 
vaccines against HIV-1 (51,126). The current therapeutic regimen, HAART based on targeting 
viral proteins, has extended the life of many people suffering from AIDS or HIV-1 infection. 
However, development of drug resistance, non-compliance due to the severe toxicity associated 
with chronic drug therapy as well as the cost of the treatment have made HAART therapy 
ineffective in controlling this pandemic (26,118,218). Therefore, there is strong need for 
developing new therapeutics. Anti-HIV drugs targeting virus-host protein-protein interactions 
represent an underexplored strategy for AIDS therapy. 
1.1.1 The HIV-1 Virion 
Unlike other cone shaped retroviruses, HIV virions are roughly spherical particles of about 120 
nm in diameter spiked with protein tufts of about 200 Å per particle, as determined by atomic 
force microscopy (AFM) (150,258). Similar to other lentiviruses, the HIV virion is enveloped 
with a lipid bilayer originated while budding from host cells [Figure 1 and (258,264)]. Since this 
lipid bilayer is derived from the host cell, it contains several cellular membrane proteins 
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including major histocompatibility antigens, actin and ubiquitin (17). Additionally, the viral 
envelope also contains about 72 copies of two major viral glycoproteins derived from Env 
(Figure 1).  Each envelope protein is composed of three copies of the heavily glycosylated 
surface protein (SU), gp120, and the transmembrane protein (TM), gp41. These proteins are 
derived from gp160 after proteolytic processing and have role in viral entry as well as syncytia 
formation (76,173).  
The 40-60 nm conical core is composed of about 2000 copies of capsid protein (CA, p24) 
and is surrounded by a matrix shell comprised of approximately 2000 copies of the matrix 
protein (MA, p17) on the inner surface of the viral membrane. Two copies of the RNA genome 
are stabilized with about 2000 copies of nucleocapsid protein (NC, p7) as a ribonucleoprotein 
complex inside the core. The capsid also encapsulates viral enzymes (Protease, Reverse 
transcriptase, Integrase) as well as accessory proteins (Nef, Vif, Vpr) [reviewed in (258)]. 
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Figure 1.  Structure of HIV-1 Virion. 
This cartoon depicts a typical HIV-1 virion, with the major structural proteins indicated. (Image 
was reproduced from a publicly available source, the National Institute of Allergy and Infectious 
Diseases.) 
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1.1.2 HIV-1 Genome and Proteins 
The HIV-1 provirus is approximately 9.8 kilobases in length and flanked by repeated sequences 
know as long terminal repeats (LTRs). The HIV-1 genome encodes 9 open reading frames 
(ORF) and gives rise to 15 proteins which include common retroviral major structural proteins; 
Gag (group-specific antigen), Pol (polymerase) and Env (envelope), two regulatory (Tat and 
Rev) as well as four accessory proteins (Vif, Vpr, Vpu and Nef) [Figure 2 (74,78,183)]. 
 
Gag 
HIV-1 gag gene encodes a 55 kDa myristoylated Gag polyprotein that self assembles at the 
membrane to form immature virion or virus-like particles (VLP) in the absence of other viral 
components (38,82). During assembly, the Gag protein recruits two copies of unspliced, full-
length genomic RNA as well as viral and cellular proteins and triggers budding of immature viral 
particles. After budding and during the process of maturation, p55 is proteolytically processed by 
the virally coded protease into MA (17 kDa), CA (24 kDa), NC (7 kDa) as well as low molecular 
weight products like p1, p2 and p6 (89).  
The myristoylated MA polypeptide stabilizes each viral particle at the membrane during 
assembly as well as transports the viral genome into the nucleus with the help of the nuclear 
transport machinery after viral entry. The p24 CA protein forms the conical viral core and 
incorporates Cyclophilin A (CypA) which is critical for viral replication. The NC polypeptide 
recognizes and binds the packaging signal of the HIV-1 genomic RNA and stabilizes the HIV-1 
genome during viral assembly. Moreover, NC facilitates reverse transcription after viral entry 
into host cell. A conserved LXXLF sequence within the p6 is required for Vpr packaging. The p6 
polypeptide is also plays important role in viral budding [reviewed in (74,115,258)].  
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LTR gag
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Figure 2. Organization of HIV-1 Genome. 
The HIV-1 proviral genome is flanked by two long terminal repeats (LTR) which contain the 
promoter elements necessary for viral gene transcription. The gag gene encodes structural 
proteins, pol encodes the essential viral enzymes reverse transcriptase, protease, and integrase, 
and the env gene encodes the envelope glycoproteins required for HIV-1 virion assembly. [This 
figure is adapted from (78)]. 
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Pol 
HIV-1 pol gene encodes viral enzymes as Gag-Pol fusion proteins through ribosomal frame-
shifting during translation involving a specific RNA motif in unspliced HIV-1 mRNA (122,197). 
The Gag-Pol polyprotein is autocatalytically processed and separates the Pol polypeptide from 
Gag. The Pol protein is further processed into protease (p10), RT (p50), RT-RNase H (p65), 
RNase H (p15), and integrase (p31).  
As mentioned above, protease is required for processing of the Gag-Pol polyprotein 
during viral maturation. RT has RNA-dependent and DNA-dependent DNA polymerase activity 
and is responsible for the generation of the double-stranded DNA copy of the viral genome with 
help of RNase H before integration into the host cell genome. As RT has no proof-reading 
activity, quasispecies of HIV-1 arise even in the same patient which can lead to drug resistance. 
After reverse transcription, the double-stranded viral genome is integrated into the host cell 
genome by integrase, which possesses exonuclease and ligase activity. As all of these enzymes 
play critical roles in HIV-1 replication, they are natural targets for anti-HIV-1 drugs [reviewed in 
(115,258)].  
 
Env 
The singly spliced env mRNA encodes a 160 kDa glycoprotein. This protein undergoes extensive 
N-glycosylation at specific Asn residues in the Golgi compartment, followed by cellular protease 
cleavage into the gp41 (TM) and gp120 (SU) proteins which exists as trimers on mature viral 
particles. The 515-residue SU protein binds to the CD4 receptor on subsets of T cells and 
macrophages and initiates viral entry. V3, one of the five hypervariable regions on the SU 
protein interacts with either the CXCR4 or CCR5 co-receptors and determines viral tropism for 
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T-cells versus macrophages, respectively. The SU protein also interacts with DC-SIGN which 
can facilitate mucosal transmission by transporting HIV to lymphoid tissues. The TM protein has 
an N-terminal fusogenic domain that mediates the fusion of the viral and cellular membranes for 
viral entry into host cell. This domain is also a promising target for anti-HIV drugs that block 
viral entry [reviewed in (74,115,258)].  
 
Tat 
Tat, the transcriptional transactivator of HIV, is expressed from a multiply spliced mRNA early 
in the viral life cycle. Transcription from the integrated HIV-1 proviral genome initiates from the 
5’ LTR with the help of cellular transcription factors like RNA Pol II, NFKB, Sp1, and TBP but 
can terminate prematurely due to abrogative elongation. Tat enhances transcriptional elongation 
by binding to a stem-loop structure on the nascent viral RNA, known as TAR (trans-activating 
response element) as a Tat-cyclin T-Cdk9 complex. Cdk9 then stimulates transcriptional 
elongation by phosphorylating the RNA polymerase II transcription complex [reviewed in 
(74,115,258)].  
 
Rev 
Rev is a 13 kDa protein expressed very early in the HIV-1 life cycle from multiply spliced 
mRNA. Rev has an arginine-rich RNA binding domain, a multimerization domain and an 
effector domain with a nuclear export signal.  Rev binds specifically to RRE (rev response 
element) sequences within singly spliced and unspliced transcripts containing the env gene 
sequence and transports them to the cytoplasm. HIV-1 proviruses with Rev mutations are 
transcriptionally active but do not produce virions [reviewed in (74,115,258)]. 
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Vif 
Vif is a 23 kDa protein important for production of highly infectious virus. Sheehy et al. 
discovered the HIV-1 replication inhibitor, apolipoprotein B mRNA-editing enzyme-catalytic 
polypeptide-like 3G (APOBEC3G), which is targeted for proteosomal degradation by Vif (237). 
In the absence of Vif, APOBEC3G is efficiently encapsidated in progeny virions and responsible 
for G to A mutations in newly synthesized cDNA by RT. These mutations arise from the 
APOBEC3G-mediated deamination of cytosine nucleotides, and this uracil-containing DNA is 
then degraded before integration.  In addition, the modified proviral DNA that does integrate 
cannot be effectively translated due to multiple stop codons. In the case of wild-type HIV-1, Vif 
directly interacts with APOBEC3G and targets this restriction factor to an 
elongin/cullin/suppressor of cytokine signaling (SOCS) box (ECS) E3 ligase complex, resulting 
in APOBEC3G polyubiquitination and subsequent degradation [reviewed in (74,189)]. We have 
recently reported that similar to HIV-1 Nef, Vif also binds and activates SFKs in yeast-based and 
in vitro kinase assays but the significance of this interaction to HIV-1 pathogenesis is currently 
unknown (168).  
 
Vpr 
Vpr is a 14 kDa protein packaged into virions by direct interaction with the p6 domain of the 
Gag protein. Vpr plays a role in ability of HIV to infect non-dividing cells like monocyte-derived 
macrophages by transporting the viral preintegration complex (PIC) to the nucleus through an 
intact nuclear membrane in the absence of mitosis. In addition, Vpr is involved in modulation of 
transcription of the viral genome, induction of apoptosis, disruption of cell-cycle control, 
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induction of defects in mitosis, facilitation of reverse transcription, suppression of immune 
activation and reduction of the HIV mutation rate [reviewed in (77,221)].  
 
Vpu 
Vpu is a 16 kDa protein expressed exclusively in HIV-1 and is expressed from the env transcript. 
Vpu is an integral membrane protein which is phosphorylated by casein kinase II, and is 
localized to the internal membranes of the cell. Vpu triggers the ubiquitin-mediated degradation 
of CD4 molecules complexed with Env and thus prevents the interference of virus assembly due 
to formation of intracellular Env-CD4 complexes. Additionally, Vpu enhances viral budding and 
viral load through the formation of ion channels which modify the electrical potential of the 
plasma membrane. The function of enhancement of viral budding by Vpu is executed by the Env 
proteins in HIV-2 and SIV, which lack Vpu [reviewed in (27,115)].  
 
Nef 
Nef is a 27 kDa myristoylated protein expressed early in the HIV-1 life cycle. Initially described 
as a negative factor for HIV-1 replication, later studies revealed that this protein has numerous 
effector functions (See section 1.2). Although, Nef is not necessary for HIV-1 replication in 
some continuous cell lines in vitro, it is essential for high titer replication in vivo as well as 
AIDS. Nef is involved in enhancement of HIV-1 pathogenesis as well as immune evasion by 
down-regulating cell surface receptors including CD4, CXCR4, CCR5 and MHC class I 
molecules. Moreover, Nef alters cell signaling pathways involved in cell proliferation, cellular 
activation, immune recognition and survival by interacting with diverse number of host-cell 
proteins (See section 1.2). Many lines of study have revealed the importance of Nef and 
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especially its interaction with SFKs in HIV-1 pathogenesis and progression to AIDS 
(58,80,102,104,132,134,141,145,228). The evaluation of this interaction and its implications for 
new anti-HIV drug discovery is the main focus of my dissertation research. 
1.1.3 HIV-1 Life Cycle 
The mature HIV-1 virion infects subsets of T lymphocytes and macrophages through interaction 
of SU (gp120) with CD4 and chemokine receptors (either CXCR4 or CCR5). After initial 
docking on cell surface, the fusogenic peptide of TM (gp41) undergoes a conformational change 
that triggers fusion of the viral envelope with the host cell plasma membrane to allow entry of 
the viral core. The core is then uncoated in the presence of CypA and the viral genomic RNA is 
reverse transcribed by RT, resulting in the formation of the pre-integration complex (PIC). With 
the help of Vpr and other cellular factors the PIC is then transported to the nucleus. The viral 
double-stranded DNA is then integrated into host chromosomes as a provirus with the help of the 
viral IN enzyme. After cellular activation, and in the presence of host transcription factors, RNA 
Pol II initiates transcription from the 5’LTR of the HIV-1 provirus. This transcription is 
enhanced by Tat binding to specific regions on newly synthesized mRNA (TAR) and results in 
production of several copies of differntially spliced genomic and sub-genomic mRNA. The viral 
Rev protein is responsible for transport of these mRNAs from nucleus to cytoplasm by binding 
the RRE in the mRNAs. After translation, the Gag and Gag-Pol polyproteins localize to the 
plasma membrane while Env proteins are translated in the ER and glycosylated in the Golgi 
apparatus. The core particles are assembled at the membrane from Gag and Gag-Pol 
polyproteins, Vif, Vpr, Nef, and the genomic RNA, and an immature virion begins to bud from 
the cell surface. Vpu assists in the assembly of SU and TM on the viral envelope by preventing 
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interaction between Env proteins and CD4. Moreover, Nef promotes endocytosis and 
degradation of cell-surface CD4 and helps in the release of immature virus from producer cells. 
After budding, the virion undergoes maturation which involves proteolytic processing of Gag 
and Gag-Pol polyproteins. These mature virions are then ready to infect new cells by binding to 
CD4 and chemokine receptors [reviewed in (74)]. 
1.1.4 HIV-1 Vaccines and Therapeutics 
The development of a globally effective and safe vaccine which induces durable immunity is the 
best approach to prevent new infections as well as to boost immunity in infected individuals. One 
major obstacle for development of a useful HIV-1 vaccine relates to global HIV-1 diversity. 
Among the three groups of HIV-1 sequences, the M group is responsible for more than 90% of 
HIV-1 infections associated with the global HIV/AIDS pandemic (111,194,205). The M group is 
further classified into nine subtypes or clades (A, B, C, D, F, G, H, J and K) which display more 
than 25% sequence variation in the Env and Gag regions (200,265). These subtypes also show 
significant diversity in global distribution. The B clade is most prevalent in America and Europe, 
while the C clade is mostly in the Indian subcontinent, China and Africa.  Other clades (A, F, G, 
H, J and K) are also prevalent in Africa (Figure 3). 
Over the last 30 years, more than 40 candidate vaccines have been evaluated in 80 phase 
I/II clinical trials.  These vaccine trials have including live attenuated, recombinant DNA, and 
subunit vaccines as well as various prime-boost strategies but no effective vaccine has been 
developed [reviewed in (51,84,85,170,224)]. Among the four vaccines evaluated in human 
clinical trials III and IIb; including Vaxgen's gp120, Merck's rAd5, and ALVAC + gp120 
(RV144), only RV144 showed modest efficacy in preventing HIV-1 infection. Inter- and 
  15 
intraclade amino acid divergence in the HIV-1 glycoprotein as well as numerous CRF allows 
selection of variants which escape from host immunity and thus is the major obstacle for the 
development of effective global HIV-1 vaccine [Figure 3 and (84)].  
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Figure 3.  HIV-1 global distribution and diversity. 
This map shows the global distribution and genetic diversity of the nine major HIV-1 subtypes, 
known as "clades," as well as major recombinants. [This figure was reproduced from a publicly 
available source, the IAVI Report, August 2003 (2)]. 
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A live attenuated vaccine was initially produced by deleting the nef gene from SIV.  
While initially very promising, infected macaques ultimately progressed to SAIDS (see section 
1.2.2). Similarly, HIV-1 vaccines based on virus-like particles (VLPs) with various 
modifications of glycoproteins and adjuvant combinations also failed to elicit neutralizing 
antibodies. Moreover, live vector or recombinant DNA vaccines expressing individual or subunit 
viral antigens failed to produce effective and protective immune responses, and even enhanced 
viral pathogenesis in some cases [reviewed in (42,84)].  
As it is very difficult to develop an effective vaccine for HIV/AIDS, we must rely on 
antiretroviral drugs to treat the HIV-1 infected population. The development of highly active 
antiretroviral therapy (HAART) has been remarkably effective in controlling viral load and 
prolonging life as well as lowering the number of new infections (4).  HAART is composed of a 
combination of three or more drugs targeting different stages of the HIV-1 life cycle.  However, 
because HIV-1 remains dormant as the integrated provirus, patients must remain on these drugs 
throughout their lifetime to avoid relapse. This lifelong treatment results in several toxicities as 
well as development of drug-resistant viruses (11,26,149,177,190,270). 
Currently, the U.S. Food and Drug Administration (FDA) has approved about 30 drugs 
which targets different stages of the HIV-1 life cycle, including virus-cell fusion, reverse 
transcription, integration and proteolytic cleavage (maturation) (260). These includes 2 multi-
class combination products (Atripla, Complera), 13 nucleoside reverse transcriptase inhibitors 
(Combivir, Emtriva, Epivir, Hivid, Retrovir, Trizivir, Truvada, Videx EC, Videx, Viread, Zerit, 
Ziagen), 6 nonnucleoside reverse transcriptase inhibitors (Edurant, Intelence, Rescriptor, Sustiva, 
Viramune, Viramune XR), 11 Protease Inhibitors (Agenerase, Aptivus, Crixivan, Fortovase, 
Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept), 1 Fusion Inhibitor (Fuzeon), 1 
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Entry Inhibitor (Selzentry) and 1 HIV integrase strand transfer inhibitor (Isentress) (260). In 
addition to these, therapy based on siRNA/shRNA targeting HIV-1 and/or host genes looks like a 
promising new approach to combat AIDS [reviewed in (290)].  
As described in detail in the next section, many studies have identified the nef gene as a 
critical virulence factor required for AIDS progression. In particular, patients infected with Nef-
defective HIV-1 took more than 15 years to develop AIDS supporting Nef as a target for drug 
development. Considering the fact that HIV replication is highly mutable, new drugs targeting 
viral accessory factors such as Nef may also select for drug-resistant HIV-1 variants. One 
approach to circumvent this problem may be to target the interaction of the viral protein with 
host cell effector proteins, or inhibit critical downstream signaling pathways triggered by these 
factors.  In this study, we showed that interaction of the HIV-1 Nef with the host signaling 
molecule Hck is highly conserved among all major clades of HIV-1. Moreover, we demonstrated 
that inhibitors of Nef-induced Hck activation are broadly active against Nef-dependent HIV-1 
replication in cell culture.  
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1.2 HIV-1 NEF 
The HIV-1 nef gene encodes a 27 kDa myristoylated protein expressed early in the HIV-1 life 
cycle (15,81,136). Initially described as a negative factor for HIV-1 replication, later studies 
showed that Nef has either no effect or a positive effect on HIV-1 replication depending on the 
host cell under study (10,106,135). More importantly, Nef is required for SIV-induced AIDS in 
Rhesus macaques, while defective or mutated forms of Nef have been detected in long-term non-
progressors infected with HIV-1 (24,58,141). Nef exerts its effects by interacting with myriad 
host cell proteins involved in cellular activation, immune recognition and survival (114,216). 
Many protein-protein interaction surfaces have been mapped on Nef which have helped to 
validate important Nef functions, such as the down-regulation of CD4 and MHC-1 molecules 
and activation of host cell signaling pathways (Figure 4).  
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Figure 4.  Structure Function relationship of HIV-1 Nef. 
Different functional motifs and domains are mapped onto a molecular model of HIV-1 Nef as 
shown. Major functions associated with of each of these motifs are described in the table as well 
as in text (Courtesy of Dr. John Engen, Northeastern University). 
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1.2.1 Nef Structure-Function relationships 
Nef has no known enzymatic activity, and appears to exert its effects by interacting with a 
diverse group of host cell proteins. The highly conserved HIV-1 Nef protein contains numerous 
well-defined structural motifs, many of which localize to the stable Nef core and are involved in 
binding to cellular proteins (Figure 4).  X-ray crystallography as well as nuclear magnetic 
resonance (NMR) has shown that Nef consists of a globular core domain (amino acids 54-205) 
and flexible N- and C-terminal loops (13,75,96,155). The comparison of HIV-1 Nef sequences 
from 186 different HIV-1 strains showed that many structural motifs are highly conserved.  
Important examples include sequences for myristoylation MGxxx(S/T), the diluecine motif 
L164L, the acidic motif E62EEE, the proline-rich motif P72xxP, and a diarginine motif R105R. 
The functional significance of each of these motifs is detailed in the following sections.  While 
HIV-1 Nef has been described to interact with a diverse group of host-cell proteins, the relevance 
of these interactions to HIV-1 pathogenesis has not been established in all cases  
(22,25,52,69,83,95,97,226,249,277).  
 
Myristyolation motif  
The flexible N-term domain of HIV-1 Nef contains the sequence MGxxx(S/T), which induces 
post-translational modification by N-myristoyl transferase (31,81). The covalent amide linkage 
of the 14 carbon saturated fatty acid to N-term Glycine at the G2 position targets Nef to the inner 
leaflet of the plasma membrane (217). This myristoylation motif is highly conserved among 
different strains of HIV-1 which highlights its importance in HIV-1 pathogenesis [reviewed in 
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(81) and (105)]. In addition to myristoylation of Nef, four N-terminal arginines between residues 
17 and 22 as well as two lysines at positions 4 and 7 are required for its membrane targeting (22).  
Mutational analysis revealed that N-terminal myristoylation of Nef is critical for HIV-1 
replication. A Nef mutant defective for this post-translational modification completely blocked 
its ability to induce MHC-1 and CD4 down-regulation (108,203). The myristoylation of HIV-1 
Nef is also required for its interaction with actin and its subcellular localization in human B and 
T cells (68). The Gly to Ala (G2A) mutation of the myristoylation site completely abolished the 
ability of Nef to drive AIDS-like disease development as well as depletion of CD4
+
/CD8
+
 
thymocytes in transgenic mice. Thus the myristoylation and other regions at the N-terminus of 
Nef (amino acids 25-35 and 57-66) are critical for mediating severe T-cell phenotypes and organ 
disease, although residues 8-17 are dispensable for these Nef functions (103). The G2A mutant 
of Nef also failed to associate with PAK2 kinase as well as development of disease of the non-
lymphoid organs (kidneys and lungs) (263). The myristoylation of Nef is also required for in 
vitro activation of STAT2, IRF3 as well as phosphorylation of α and β subunits of the IκB kinase 
complex and of JNK, ERK1/2, and p38 mitogen-activated protein kinase family members in 
human monocyte-derived macrophages (MDMs) (167). Nef myristoylation is essential for high 
affinity binding to calmodulin suggesting its role in calcium signaling (171). Myristoylated Nef 
also plays an important role in Nef-mediated activation of NFAT, NFKB, and induction of IL-2 
expression.  The Nef-driven pathways enhance transcription from the viral LTR as well as HIV-1 
replication in T cells stimulated by CD3 and CD28 (269,288). Thus myristoylation of HIV-1 Nef 
is a very important post-translational modification critical for HIV-1 pathogenesis. 
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SH3 domain-binding motif (PxxP) 
One important group of Nef-interacting proteins includes members of the Src protein-tyrosine 
kinase family (64).  Nef directly bind and activates a subset of SFKs, namely Hck, Lyn and c-Src 
(154,156,226,256). Nef interacts with SFKs by binding to their SH3 domains through its 
conserved PxxPxR sequence.  HIV-1 Nef is a relatively high affinity ligand for the Hck SH3 
with affinity constants of in the nM to low μM range, depending upon the allelic variant (see 
Chapter 3 for more details).  Structural studies of the Nef-SH3 interface reveals that the 
interaction involves not only the conserved PxxPxR motif on Nef but also a hydrophobic pocket 
formed by the three-dimensional fold of the Nef core region (96,155).  This pocket 
accommodates an Ile residue on the SH3 domain RT loop, and is found only in the SH3 domains 
of Hck and the related Src-family member, Lyn.  Subsequent studies revealed that Nef binding 
induces constitutive activation of Hck and other SFKs by displacing the SH3 domain from its 
negative regulatory interaction with the SH2-kinase linker on the back of the kinase domain 
(35,156,180).  Activation requires both the Nef PxxPxR motif and hydrophobic pocket, and may 
produce a unique activated conformation of the partner kinase (45,156,201).  In addition to these 
highly conserved Nef regions directly involved in SH3 engagement, studies of Nef alleles 
derived from long-term non-progressors have shown that residues at a distance from the SH3 
binding site also impact Nef-dependent Hck activation, possibly through an allosteric mechanism 
[Figure 6 and reference (257)]. Nef-induced AIDS-like disease is completely reversed in mice 
expressing a Nef PxxP mutant unable to bind to Hck SH3 domain underscoring the importance 
of this motif in HIV-1 pathogenesis (102,104). The PxxPxR motif of Nef is not required for 
down-regulation of cell surface CD4 receptors but vital for enhancement of HIV-1 replication in 
infected peripheral blood mononuclear cells (PBMC) as well as SIV replication in macaques 
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(132,226). However, the ability of HIV-1 Nef to downregulate MHC class I receptors, a key 
function in immune evasion of HIV-infected cells, requires an interaction between the Nef PxxP 
motif and SFK SH3 domain (25,40,91,119). Similarly, the SH3-binding motif of Nef is required 
for down-regulation of the MHC class Ib protein HFE, which regulates iron homeostasis in 
macrophages (62). Additionally, the SH3-binding motif of Nef in conjunction with the 
myristoylation signal sequence is required for constitutive Hck-dependent STAT3 activation and 
proliferation of a myeloid cell line (34). The intact SH3-binding motif of Nef is also required for 
intracellular Lck accumulation as well as for its ability to interfere with the functions of the 
immunological synapse (99).  
   
The dileucine motif: 
One of the important functions of HIV-1 Nef is down-regulation of the cell surface receptor CD4 
to help viral infection and spread as well as to block super-infection (21,56,161,163,225). Unlike 
SIV Nef where a tyrosine-based motif is involved (152,207), HIV-1 Nef has a highly conserved 
dileucine motif which interacts with components of the host cell protein trafficking machinery 
and act as an internalization signal for CD4 down-regulation (9,30). The conserved dileucine 
motif (L164L) sequence is localized to the carboxy-terminal disordered loop of HIV-1 Nef (90). 
The dileucine motif and tyrosine-based motif are two well characterized signals that direct 
cellular proteins to clathrin-coated vesicles (139). The L164L sequence of Nef binds directly and 
specifically to the beta-adaptin subunit of the clathrin adaptor complexes AP-1 and AP-2.  
Mutation of the dileucine motif impairs the ability of Nef to localize into clathrin-coated vesicles 
as well as to down-regulate CD4 without affecting down-regulation of MHC class I molecules 
(30,90).  
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The acidic motif: 
HIV-1 Nef facilitates the replication of HIV-1 in the face of host immunity by down-regulating 
MHC class I molecules of the infected cells.  HIV-1 Nef triggers the down-regulation of MHC 
class I molecules by binding to the trafficking adaptor protein PACS2 through a mechanism that 
requires a conserved N-terminal acidic motif (E62EEE). This interaction targets Nef to the trans-
Golgi compartment where it assembles a multi-kinase complex (SFK/ZAP-70/PI3K) to 
internalize MHC I molecules (18,25,91,119). Sequence alignment of HIV-1 Nef derived from 
186 different strains revealed that the acidic motif (E62EEE) is highly conserved with the 
variation is the insertion of fifth acidic residue (E or D) and non-conservative insertion of a Gly 
only in eight sequences [reviewed in (81)]. 
 
The diarginine motif: 
HIV-1 Nef interacts with several cell signaling molecules and activates T cells to facilitate HIV-
1 replication. Nef interact with and activates the cellular serine/threonine p21-activated kinase, 
Pak2 (16,69,214). In addition to the SH3-binding motif, a highly conserved diarginine motif 
(R105K/R) of Nef is required for Nef-mediated Pak2 activation (69,70,227). This motif is 
present at the N-terminus of helix α4 of Nef with the first Arg absolutely conserved and the 
second replaced with Lys or Gln. The presence of these two positively charged amino acids have 
a strong impact on helix formation as well as protein stability [reviewed in (81)]. Nef-mediated 
Pak2 activation is important for its antiapoptotic effects, induction of LTR activity and 
cytoskeletal rearrangement (70,278). Nef-mediated activation of Pak2 is important in progression 
of SAIDS in macaques as well as for AIDS-like disease development in HIV-1 transgenic mice 
(102,104,229). 
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1.2.2 Nef in HIV-1 Pathogenesis  
Nef, an accessory protein only present in primate lentiviruses, is not required for HIV-1 
replication in vitro (253) but is essential for high titer viral replication in vivo 
(8,103,174,222,241) and AIDS pathogenesis (58,132,133,146). HIV-1 and SIV both weaken the 
immune system by causing depletion of CD4
+
 lymphocytes resulting in acquired 
immunodeficiency syndrome (AIDS) in humans and macaques respectively 
(29,159,172,175,176).  
Nef is required for progression of simian AIDS, which resembles human AIDS in terms 
of depletion of CD4
+ 
lymphocytes, muscle wasting, and mortality (131).  In this AIDS model, 
Nef-deleted SIV replicated very poorly compare to wild-type SIV, and macaques infected with 
Nef-defective SIV failed to develop SAIDS (132). Furthermore, a live attenuated SIV vaccine 
lacking the Nef gene completely protected macaques from challenge by intravenous inoculation 
of live, pathogenic SIV. Interestingly, when macaques were infected with live SIV having a Nef 
gene with a premature stop codon, the Nef reading frame was eventually restored, suggesting 
strong selective pressure for restoration of Nef expression in the context of SAIDS pathogenesis 
(57,132). The importance of Nef in AIDS progression became further evident from cohort 
studies of long-term non progressors (LNTPs) infected with Nef-defective HIV-1. These 
individuals remained asymptomatic for long periods of time and took more than 15 years to 
develop reduced CD4
+
 lymphocyte counts (24,58,87,141). Moreover, Hanna et al. showed that 
the expression of Nef alone under the control of a hybrid CD4 promoter in the HIV-1 target cell 
population (CD4
+
 lymphocyte and macrophages) is sufficient to cause AIDS-like disease 
development in transgenic mice. (102,103). Along similar lines, Nef is required for high titer 
HIV-1 replication as well as CD4
+
 lymphocyte depletion in SCID-hu and hu-PBL-SCID mice 
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(98,123,124). While the specific mechanisms responsible for the impact of Nef on HIV disease 
are not clear, Nef has several important functions related to HIV-1 replication and T-cell 
activation that are likely to play a major role.  These are described in more detail below.HIV-1 
infectivity in both lymphoid and myeloid cell lines is enhanced 100- to 10,000-fold by Nef-
competent HIV-1 (48). In addition, Nef enhanced both reverse transcription as well as p24 capsid 
production irrespective of cell line used (233). Moreover, infection of mitogen-activated PBMCs 
also showed the enhancement of HIV-1 replication by Nef. This effect was more pronounced 
when unstimulated PBMCs were infected with Nef
 (-)
 versus Nef
 (+)
 viruses followed by mitogen 
activation, suggesting that those Nef-defective viruses required much more time to replicate to 
appreciable levels. These studies also demonstrated a positive effect of Nef on HIV-1 replication 
in macrophages (178,245). This positive effect of Nef on HIV-1 replication could be due to Nef-
mediated enhancement of proviral DNA synthesis (10) and an increase in secondary viral spread 
in PBMC cultures (178). Nef also up-regulates the DC-SIGN receptor on dendritic cells (DC) 
which contributes to viral spread from DCs to T-lymphocytes [reviewed in (12)]. Nef is also 
involved in cytoskeleton reorganization by interacting with Vav1, a guanine nucleotide exchange 
factor for Rho family GTPases.  This pathway may contribute to Nef-induced activation of Pak2, 
which is required for virion fusion, trafficking of the viral core as well as efficient reverse 
transcription (39,70,160,215,234) and [reviewed in (12)].  Similarly, Nef increases the lipid 
content in progeny virions by directing them to lipid rafts enriched in sphingolopids and 
cholesterol, which may also help to enhance viral infectivity [reviewed in (12)]. 
Another important function of Nef is to create an optimal environment for HIV-1 
replication by activating T cells. Nef induces T cell activation by short-circuiting pathways 
involved in TCR signaling as well as the secretion of cytokines by macrophages which has a 
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paracrine effect on T cell activation (20,71,143,204,231,241,242,250,251). Gene-expression 
profiling in Jurkat cells showed that Nef expression triggers a transcriptional program which 
mimics anti-CD3 T activation. This study also showed that Nef downregulates IL-16 and YY1, 
which are negative regulators of HIV-1 transcription, while upregulating factors that, promote 
transcription, including Tat-SF1, U1 SNRNP, and IRF-2 (241).  
Thus, Nef indeed has numerous effector functions that enhance HIV-1 replication and 
contribute to AIDS progression, and therefore represents a promising target for therapeutic 
intervention in AIDS. In this dissertation research project, we first validated the interaction of 
Nef and host cell signaling molecules, focusing on the SFKs because of their potential as targets 
for drug discovery. The basic structure-function relationship governing Src-family kinase 
activity and the mechanisms by which this is influenced by Nef is described in the next section. 
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1.3 SRC FAMILY KINASES 
The Src-family of protein-tyrosine kinases (SFKs) consists of eight related kinases in mammals: 
c-Src, Fyn, c-Yes, Hck, Fgr, Lck, Lyn and Blk. Three of these (Src, Yes and Fyn) are expressed 
ubiquitously while the others exhibit expression patterns more restricted to hematopoietic cells 
(37,255). Hck and Fgr are expressed in macrophages (274,291) while Lck and Fyn are expressed 
in T cells (195); both of these cell types represent major host cells for HIV-1. SFKs are involved 
in regulating cell growth, survival, differentiation, cellular adhesion, migration, invasion, 
synaptic transmission as well as both acquired and innate immune responses (37,198,199). As 
SFKs are key regulators of cell signaling, the loss of regulation of SFK activity has been 
associated with several pathological states, including AIDS (43,104,121,144). 
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Figure 5. Crystal structure of the downregulated form of the macrophage Src-family 
member, Hck, and its activation by Nef binding. 
A) The linear arrangement of the Hck domains is shown at the top, and corresponding colors are 
mapped onto the crystal structure below it. Shown are the unique N terminal (N; not in crystal 
structure), SH3, SH2, and kinase domains (N- and C-lobes) as well as the negative regulatory 
tail. The SH2-kinase linker is shown in orange. The location of the activation loop is indicated 
(A-loop), and tyrosine phosphorylation sites (loop and tail) are shown in red. B) Hck, like other 
members of the Src-kinase family, is held in the downregulated conformation by intramolecular 
interactions of the SH2 domain (blue) with the C-terminal tail (cyan) as well as the SH3 domain 
(red) with the SH2-kinase linker, which forms the PPII helix shown (orange).  The HIV Nef core 
engages the Hck SH3 domain via a conserved PPII helix (purple), causing SH3 displacement 
from the linker and constitutive kinase activation. (PDB coordinates used in this model: 
Downregulated Hck: 1QCF; Nef core: 1EFN; Hck: Nef complex: 1QCF, 1EFN, and 3NHN.  
Alignment and modeling via PyMol; model of Hck: Nef complex, courtesy of John Jeff Alvarado, 
Department of Structural biology, University of Pittsburgh School of Medicine). 
SH3
SH2
N-lobe
C-lobe
Tail
aC
A-loop
Y416
SH3 SH2 N-lobeN C-lobe
Y527
A
 
  31 
1.3.1 Src Family Kinase Structure 
The determination of the crystal structures of near-full length c-Src as well as Hck in their 
downregulated conformations has provided critical insights into our understanding of the three-
dimensional arrangement of their structural domains and their contribution to regulation of 
kinase activity (55,273,281). All SFKs contain a similar N- to C-terminal arrangement of 
structural domains (Figure 5). The myristylated N-terminal unique region (Src-homology 4 
domain) is followed by a Src-homology 3 (SH3) domain, a Src-homology 2 (SH2) domain, a 
regulatory SH2-kinase linker, a bi-lobed tyrosine kinase domain (Src-homology 1 domain), and a 
C-terminal negative regulatory tail [reviewed in (64)].  
 
Unique Domain (SH4 Domain) 
The amino terminal unique domains (SH4 domain) are typically 50-80 residues in length and 
contain sequences for myristoylation and in most cases palmitylation that direct SFKs for 
membrane attachment (239). This membrane targeting of SFK is essential for full functional 
activity and signal transduction (37,128,286).  SH4 domains are the only non-conserved regions 
within the Src kinase family and may determine specificity for downstream targets in some cases 
(195). For example, a dicysteine motif in the unique domain of Lck determines its ability to bind 
to the TCR co-receptors CD4 and CD8α.  In another example, switching the unique domain of c-
Yes for that of c-Src blocked c-Src-mediated activation of PI-3 kinase, phosphorylation of c-Raf 
and Akt and downregulation of RhoA-GTP, which is involved in dynamic regulation of actin.  
(247,259).  
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SH3 Domain 
Src-family kinase SH3 domains are about 55-70 amino acids in length and have small 
hydrophobic grooves on their outer surface suitable for binding target peptides rich in prolines 
(50,148,289). These proline-rich target sequences generally form a left-handed polyproline type 
II (PPII) helix which associates with the hydrophobic surface of the SH3 domain (148,186). The 
central proline in this PPII helix interacts with a key tryptophan located within one of the 
hydrophobic grooves on the SH3 binding surface (66,232). In addition to interacting with 
signaling partners, the SH3 domain also regulates the kinase activity by binding to the linker 
region between SH2 and kinase (210). This SH2-kinase linker forms a PPII helix in the structure 
of the downregulated kinase. 
 
SH2 Domain 
SH2 domains are about 100 amino acids in length and bind to short peptide sequences containing 
a phosphotyrosine residue (50,148,267). The canonical high-affinity peptide motif for interaction 
with SFK SH2 domains is pTyr-Glu-Glu-Ile (pYEEI). This sequence forms a structure similar to 
a two-pronged plug which binds to a two-holed socket formed by the structure of the SH2 
domain. One hole in the SH2 domain accommodates the phosphorylated tyrosine while the other 
shallower hole recognizes a hydrophobic isoleucine residue [(243,244,267) and reviewed in 
(64)]. All SH2 domains contain an invariant arginine residue (Arg174 in c-Src) essential for 
interaction with the phosphorylated tyrosine (266). The SH2 domains bind only to 
phosphorylated tyrosine target sequences (148).  
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Kinase Domain 
The bi-lobed kinase domains (SH1) of SFKs are responsible for recognition of and catalytic 
transfer of a phosphate group to the target peptide sequence. The catalytic site is surrounded by 
key amino acid residues integral to the binding of both the substrate sequence and ATP (142). 
This region is highly conserved among SFKs, and the kinase domain structures of c-Src, Fyn, 
and Lck can be interchanged without loss of functional activity (28,138,282). The structure of 
the kinase domain is highly conserved within the members of the protein tyrosine kinase family 
including insulin receptor kinase, C-terminal Src kinase (Csk) and Abl kinase 
(116,117,151,188,191). The Asp386 and Asn391 within the kinase domain are critical for 
coordination of magnesium ions involved in ATP binding. Similarly, Asp404 of the conserved 
DFG motif (amino acids 404-406), coordinates ATP-Mg++, while the conserved Lys295 and 
Glu310, form an ionic interaction critical to maintaining the active conformation [Note: residue 
numbering is based on chicken c-Src] (28,100,222). This active site is formed by the space 
between the small and large lobes of the kinase domain, and access to this site is regulated in part 
by a highly mobile element known as the activation loop, which contains an auto-
phosphorylation site (Tyr416). Phosphorylation of the activation loop tyrosine is associated with 
an increase in kinase activity (54,210). In the unphosphorylated state, Tyr416forms hydrogen 
bonds with Arg385 and Asp386 and effectively blocks the opening of catalytic site, whereas the 
phosphorylation of Tyr416 disrupts these interactions, causing displacement of the activation 
loop and opening of the catalytic site (5,55,230,280,282). Phosphorylation of Tyr416 leads to 
extended conformation that turns the activation loop to the “on” position that is believed to favor 
entry of ATP and peptide substrate into the catalytic cleft (109). 
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C-terminal tail 
The carboxy-terminal tails of SFKs are about 15-17 amino acids in length and contain a 
suboptimal tyrosine-based SH2-binding motif (243). The C-terminal tail is critical for the 
negative regulation of kinase activity. The conserved tail tyrosine residues of SFKs are 
phosphorylated by a distinct regulatory kinase known as Csk (for C-terminal Src kinase) as well 
as a closely related kinase known as Chk (47,187). The phosphorylation of this inhibitory 
tyrosine (Tyr527 in c-Src) induces intramolecular binding of the tail to the SH2 domain, which 
helps to stabilize the downregulated conformation (37). One mechanism of SFK activation 
involves dephosphorylation of Tyr527 by cellular phosphatases.  For example, activation of Lck 
in the context of TCR signlaing involves tail dephosphorylation by the the transmembrane 
phosphatase CD45, which releases intramolecular binding of SH2 to phosphotyrosine of the tail 
and promotes kinase activation (113,211,223,254). 
1.3.2 Intra-molecular Regulation 
As described in the preceding sections, the SH2 domains of SFKs interact with the tyrosine-
based motif in the C-terminal tail, while the SH3 domains interact with PPII helices formed by 
the linker joining the SH2 and kinase domains. These two interactions are critical in kinase 
regulation by locking the kinase in the inactive conformation revealed in the X-ray crystal 
structures of c-Src and Hck (210,240,273,281).  
The crystal structures of c-Src and Hck revealed the interaction of the SH3 domain with a 
suboptimal SH3-binding sequence linking the SH2 and kinase domains (240,273,281). The SH3-
binding motif of the SH2-kinase linker is not well conserved among the SFK family and poorly 
resembles the canonical PxxP SH3-binding motif typical of high affinity PPII-based SH3 ligands 
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(6). This interaction alone is critical to downregulation of kinase activity. For instance, 
replacement of the two prolines in the Hck linker with alanines is sufficient to induce activation 
of the kinase in rodent fibroblasts via SH3 domain release (36). Conversely, substitution of the 
Hck linker lysines with prolines strongly enhances the binding of the linker to the SH3 domain, 
demonstrating that the wild-type linker region indeed mediates suboptimal SH3 binding (157).  
As described in detail above, Nef encodes a conserved proline-rich SH3-binding motif which has 
a high affinity for the SH3 domains of Hck and Lyn. This Nef motif therefore displaces the Hck 
SH3 domain from its regulatory position on the SH2-kinase linker and activates Hck through an 
SH3-domain displacement mechanism (154,180).  
The interaction between the SH2 domain and the tyrosine-based SH2-recognition motif 
of the C-terminal tail is another key component of intra-molecular regulation of SFK activity. 
The high-resolution X-ray crystal structures of the inactive forms of c-Src and Hck revealed that 
the SH2-tail interaction holds SFKs in the down-regulated state (230,240,273,280,281). 
Replacement of the native Hck tail sequence with the high-affinity SH2-binding sequence YEEI 
yields a protein that adopts an auto-downregulated conformation (230). The Hck-YEEI molecule 
does not require Csk to adopt the inhibitory conformation, suggesting that a low level of 
autophosphorylation at the tail is sufficient to drive the molecule into a stable downregulated 
structure (164). The tight SH2-tail connection generated with the YEEI sequence is, unlike the 
wild-type sequence, refractory to release in the presence of an SH2-binding peptide (210). Even 
in the presence of SH3-linker contact, disruption of the SH2-tail interaction via mutation of 
Tyr527 causes a marked increase in kinase activity (157). Moreover, the activation of SFK by 
growth factor receptor tyrosine kinases involve SH2-dependent recruitment to the activated, 
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autophosphorylated form of the receptor; causing displacement of SH2-negative regulatory tail 
interaction (198). 
1.3.3 Binding and Activation of SFK by HIV-1 Nef 
SFK activity is regulated by the abrogation of intra-molecular interactions of SH3 and/or SH2 
domains of SFKs can stimulate kinase activity via displacement of the inhibitory regulatory 
modules. Our laboratory and others have shown that HIV-1 Nef specifically binds and activates 
subsets of SFK namely Hck, Lyn and c-Src through displacement of SH3-linker interaction 
(35,154,156,226,256). The mechanism by which Nef induced Hck activation is modeled in 
Figure 5. 
The Hck tyrosine kinase is strongly expressed in macrophages and dendritic cells 
(213,291), important target cells for HIV-1 infection.  The SH3 domain of Hck recognizes the 
PPII motif of the Nef core domain, and Hck:Nef binding is blocked by proline-to-alanine 
mutations in Nef (45,226). Additionally, the hydrophobic pocket within the Nef core domain 
binds a key isoleucine residue in Hck, Ile96, and mutation of either Ile96 or key residues within 
the Nef pocket, such as Trp90, abrogates Nef binding to Hck (45,154). Other residues within the 
Nef hydrophobic pocket, such as Tyr120, have also been found to be critical for Nef-mediated 
binding and activation of Hck [Figure 6 (45)]. The HIV-1 Nef-Hck interaction is strongly 
implicated in AIDS progression. Suppression of Hck expression with antisense oligonucleotides 
dramatically inhibits M-tropic HIV-1 replication in primary human macrophages (145). In brain-
derived microglial cells, HIV-1 infection induces Nef-dependent Hck activation; suppression of 
Nef-Hck activity via expression of dominant-negative Hck or CD45 phosphatase inhibits HIV 
replication (134).  
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Figure 6. Structural basis of Nef: SFK interaction. 
Nef interacts with the SH3 domains of Src family kinases (SFKs) via a highly conserved PxxPxR 
motif as well as hydrophobic pocket residues F90, W113, and Y120.  A close-up of the Nef: SH3 
domain interface is shown on the right, and also includes a polar contact between Nef R77 and 
SH3 domain RT loop residue D100.  (Model based on the crystal coordinates of Lee et al. [PDB: 
1EFN; (155).] 
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The Lyn tyrosine kinase is expressed in myeloid cells, as well as in brain and B cells (283). 
Similar to Hck, Lyn is the only other SFK that contains the SH3 domain Ile96 residue important 
for binding to the Nef hydrophobic pocket (45,154). Several studies have reported the ability of 
Nef to bind the Lyn SH3 domain, full-length Lyn as well as the Nef-mediation activation of Lyn 
(33,35,41,157,226).  
c-Src is the proto-typical member of the Src kinase family and exhibits broader 
expression patterns including all HIV target cell types. Unlike Hck and Lyn, c-Src lacks the Ile96 
residue implicated in high-affinity binding to the Hck-SH3 domain to Nef, and instead encodes 
an arginine at this position (154,155,273). Nef binds the SH3 domain of c-Src, though with a 
lower affinity than the Hck SH3 domain as well as full-length c-Src (14,33,45). Though Nef does 
not induce c-Src activation in a fibroblast transformation assay, Nef was shown to activate c-Src 
using a yeast-based kinase assay as well as in a model of HIV-associated nephropathy utilizing 
glomerular podocytes from HIV-transgenic mice (33,110,256).  
Other than Hck, Lyn and c-Src, no evidence for direct association or activation of other 
Src-family members present in HIV-1 target cells has been reported.  A major goal of this 
dissertation project, therefore, was to use a well-defined system to evaluate the range of SFKs 
that are HIV-1 Nef targets.  Furthermore, we sought to establish whether the activation of Hck, 
Lyn and c-Src was a general property of representative Nef proteins derived from all of the major 
subtypes of HIV-1.  These studies were critical to establish the profile of SFKs that represent 
general Nef effectors, an important step in target validation for novel antiretroviral drug 
discovery. 
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2.0  STATEMENT OF HYPOTHESIS AND SPECIFIC AIMS 
2.1 HYPOTHESIS 
Nef is a small myristoylated protein expressed early in the HIV-1 replication cycle that is 
essential for high titer viral replication and AIDS progression. Because Nef lacks enzymatic 
activity, it exerts its effects by interacting with various host cell proteins involved in cellular 
activation, immune recognition and survival. In particular, Nef interacts with the SH3 domains of 
Hck and other SFKs through its highly conserved proline-rich (PxxPxR) motif and hydrophobic 
pocket.  Nef alone is sufficient to produce AIDS-like symptoms in mice and is required for SIV-
induced AIDS in monkeys. Nef-induced AIDS-like disease is delayed in the absence of Hck in 
the transgenic mouse model. Our laboratory has shown that HIV-1 Nef specifically activates 
Hck, Lyn and c-Src. 
We hypothesize that Nef mediated activation of specific SFKs is a general property of Nef 
and is required for HIV-1 replication in macrophages and T cells and therefore represents 
a novel therapeutic target for drug intervention.  
To test this hypothesis we propose the following two specific aims: 
1) Evaluate the ability of representative Nef alleles from all HIV-1 clades to activate SFKs and 
2) Evaluation of inhibition of HIV-1 replication with novel small molecule inhibitors of Nef 
signaling. 
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2.2 SPECIFIC AIMS 
Aim 1:  Evaluate the ability of representative nef alleles from all HIV-1 clades to activate 
specific SFKs:  
Nef proteins of all M-group HIV-1 clades (A, B, C, D, F, G, H, J and K) have a conserved 
PxxPxR polyproline type II helix responsible for binding to the SH3 domain of SFKs. Our 
laboratory has shown that Nef-induced Hck activation requires not only the PxxPxR motif, but 
also a hydrophobic pocket that interacts with the RT-loop of the SH3 domain. In this aim, I 
evaluated the interactions of Nef proteins representative of all major non-recombinant HIV-1 
clades with Src-family members expressed in HIV-1 target cells (Hck, Lck, Lyn, Fyn, Fgr, and c-
Src). The binding of HIV-1 Nef to the SH3 domain of Hck was evaluated using GST pull-down 
assays as well as surface plasmon resonance spectroscopy. Nef-mediated SFK activation was 
evaluated using in vitro kinase assays with recombinant proteins as well as a yeast-based system 
previously developed in our laboratory. These studies showed that HIV-1 Nef selectively 
activates the Src-family members Hck, Lyn and c-Src by binding to their SH3 domains.  
Furthermore, patient-derived Nef alleles from brain and peripheral organs also demonstrated 
strong Hck activation in the yeast-based assay. Together, these results demonstrate that SFK 
activation is a general property of HIV-1 Nef, helping to validate Nef: SFK complexes as 
therapeutic targets. 
 
Aim 2:  Evaluation of inhibition of HIV-1 replication with novel small molecule inhibitors 
of Nef signaling:  
Studies in transgenic mice have shown that CD4 promoter-directed expression of Nef alone can 
cause AIDS-like disease in mice. This phenotype is partially reversed in Hck-null animals and is 
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completely abrogated with a PxxPxR mutant of Nef that can no longer bind to SH3 domains. 
These findings strongly indicate that inhibition of the Nef-SFK signaling pathway may inhibit 
HIV-1 pathogenesis. Our group has recently identified several novel classes of Nef-dependent 
antiretroviral compounds using high-throughput screening assays for inhibitors of Nef-induced 
Hck activation. In this Aim, I screened these compounds to test their ability to inhibit Hck 
activation by recombinant primary Nef proteins in vitro. Similarly, the broad specificity of these 
compounds was evaluated for the inhibition of Nef-dependent HIV-1 replication in U87MG and 
CEM-T4 cells using HIV-1 NL4-3 chimeras expressing the major nef alleles clade set.  
Replication of all HIV-1 Nef chimeras was potently inhibited by two distinct classes of small 
molecules, one that targets Nef directly (the phenylpyrazolyldiazine analog PPD-B9) and a 
second that selectively inhibits SFKs when Nef is bound (diphenylfuropyrimidine analogs).  
These results validate the Nef-Hck signaling axis as a viable target for development of broad-
based inhibitors as a new approach to anti-retroviral therapeutics. 
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3.0  ACTIVATION OF HCK, LYN AND C-SRC IS A GENERAL PROPERTY OF 
HIV-1 NEF ALLELES FROM ALL M-GROUP HIV-1 CLADES* 
 
*Some of the work presented in this chapter has been published in PLoS ONE: 2012 
7(2):e32561. 
 
Purushottam S. Narute
1, 2
 and Thomas E. Smithgall 
2  
 
1
Department of Infectious Disease and Microbiology, Graduate School of Public Health, 
University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America 
 
 
2
Department of Microbiology and Molecular Genetics, School of Medicine, University of 
Pittsburgh, Pittsburgh, Pennsylvania, United States of America 
 
 
 
 
 
 
 
 
 
With kind permission from PLoS ONE: 
Narute, P.S. and Smithgall, T.E. 2012  Nef alleles from all major HIV-1 clades activate Src-
family kinases and enhance HIV-1 replication in an inhibitor-sensitive manner.  PLoS ONE 
7(2):e32561. 
 
 
  43 
 
3.1 ABSTRACT 
The HIV-1 accessory factor Nef is important for high-titer viral replication and AIDS 
progression.  Nef function requires interaction with many host cell proteins, including specific 
members of the Src kinase family.  Our laboratory and others have shown that Nef specifically 
binds and activates subsets of SFKs namely Hck, Lyn and c-Src. All of these previous studies 
have used common laboratory alleles of Nef, including SF2 and NL4-3. It is necessary to 
evaluate this property of Nef using primary Nef alleles in order to target this interaction for 
therapeutic intervention. Nef proteins from HIV-1 clades (A, B, C, D, F, G, H, J and K) have a 
conserved PxxPxR polyproline type II helix which is responsible for binding to the SH3 domain 
of SFKs. Our laboratory has shown that Nef-induced Hck activation requires not only PxxPxR 
motif, but also a hydrophobic pocket that interacts with the RT-loop of the SH3 domain. The 
amino acid residues at a distance from the SH3 binding domain affected Nef-Hck complex 
formation and subsequent kinase activation. These observations strongly suggest that sequence 
alignments of nef alleles alone may not be predictive of Nef and SFKs interactions. In this aim, 
we first evaluated the ability of recombinant purified primary Nef proteins to bind Hck SH3 
domain using GST pull-down assay as well as Surface Plasmon Resonance. Next, we evaluated 
the ability of these Nef proteins to activate SFKs expressed in HIV-1 target cells. In summary, 
we demonstrate that Nef proteins derived from all of the major subtypes of HIV-1 responsible 
for the global pandemic specifically bind and activate the same subset of SFKs. These results are 
significant because they establish for the first time that host cell SFK signaling is activated by all 
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variants of HIV-1 Nef, and that inhibition of this pathway may represent a broadly useful 
strategy to combat HIV/AIDS. 
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3.2 INTRODUCTION 
The HIV-1 nef gene encodes a small myristoylated protein expressed early in the HIV-1 life 
cycle (15,81,136). Nef, one of several accessory factors unique to primate lentiviruses, is not 
required for HIV-1 replication in vitro but is essential for high-titer replication in vivo 
(10,107,178,226,245,253). Nef is also an important factor for HIV-1 pathogenesis and AIDS 
progression (67,127,206). For instance, introduction of a premature stop codon in the nef gene of 
SIV delayed simian AIDS progression and reduced viral load. Moreover, macaques immunized 
using this strategy, were protected from intravenous challenge with pathogenic SIV (57,132). 
However, some animals infected with non-pathogenic, nef-mutant SIV showed in vivo repair of 
the mutation and progression to AIDS-like disease, suggesting strong pressure to maintain Nef 
function (132,228,272). Similarly, defective or mutated forms of Nef have been detected in long 
term non-progressors infected with HIV-1 underscoring the importance of Nef in AIDS 
pathogenesis (58,80,140,141,153,169).  Finally, the CD4 promoter-directed expression of Nef 
alone to HIV target cells in transgenic mice is sufficient for the development of an AIDS-like 
syndrome characterized by CD4
+
 T cell depletion, diarrhea, wasting, and 100% mortality (102), 
supporting a major role for Nef in HIV-1 pathogenicity. 
Nef has no known enzymatic activity and instead enhances viral replication and 
pathogenesis by interacting with various host cell proteins and altering cellular signaling 
pathways.  HIV-1 Nef interacts with diverse number of host-cell proteins involved in cellular 
activation, immune recognition and survival (73,125,212,279). Many protein-protein interaction 
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surfaces of Nef have been mapped which reveal key functions such as the down-regulation of 
CD4 and MHC-1 molecules and activation of cell signaling pathways (Figure 4).   
One important group of Nef-interacting proteins includes members of the Src protein-
tyrosine kinase family. Earlier studies revealed that Nef interacts with the isolated Src homology 
3 (SH3) domains from Src family members expressed in HIV target cells, including Fyn, Hck, 
Lck, Lyn and c-Src (13,14,32,45,92,93,226). Nef directly binds and activates a subset of SFKs, 
namely Hck, Lyn and c-Src (35,154,156,226,256). Of these, Hck is strongly expressed in 
macrophages and dendritic cells, while c-Src and Lyn exhibit broader expression patterns 
including all HIV target cell types.  
Structural studies of the Nef-SH3 interface reveals that the interaction involves a highly 
conserved PxxPxR motif on Nef, which forms the polyproline type II helix typical of SH3 
ligands as well as Ile96 within the RT-loop of the Hck SH3 domain, which fits into a 
hydrophobic pocket formed by the three-dimensional fold of the Nef core region (96,155). Both 
of these interactions are required but not sufficient for high affinity binding of Nef to Hck SH3 
domain (35,45). Subsequent studies revealed that Nef binding induces constitutive activation of 
Hck and other SFKs in vitro and in cell-based systems including fibroblasts, myeloid cell lines, 
yeast and HIV-infected primary macrophages (34,35,145,180,256,287). In the down-regulated 
conformation of Hck, its SH3 domain associates with the polyproline type II helix formed by the 
linker connecting the SH2 and kinase domains (230,240). This interaction is further stabilized by 
the interaction of the SH2 domain with the C-terminal tail, which is phosphorylated on a 
conserved tyrosine residue by the negative regulatory kinases Csk and Chk (47,273,280,281). 
HIV-1 Nef activates Hck and other SFKs by displacing the SH3 domain from its negative 
regulatory interaction with the SH2-kinase linker on the back of the kinase domain (35,156,180). 
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Nef-mediated activation of Hck requires both the Nef PxxPxR motif and hydrophobic pocket, 
and does not require tail dephosphorylation or displacement from the SH2 domain suggesting 
this interaction may produce a unique activated conformation of the partner kinase (45,156). In 
addition to these highly conserved Nef regions directly involved in SH3 engagement, studies of 
Nef alleles derived from long-term non-progressors have shown that residues at a distance from 
the SH3 binding site also impact Nef-dependent Hck activation, possibly through an allosteric 
mechanism (257). Thus sequence alignments alone cannot necessarily predict the ability of 
primary Nef sequences to induce kinase activation. 
Several studies have reported the importance of Nef-mediated Hck activation in HIV-1 
pathogenesis and AIDS progression. For Instance, there is strong positive correlation between 
Hck expression and high-titer replication of macrophage-tropic HIV-1 in macrophages.   
Suppression of Hck expression with antisense oligonucleotides dramatically inhibits M-tropic 
HIV-1 replication in primary human macrophages (145). Moreover, Kim et al. showed that HIV-
1 infection induces Nef-dependent Hck activation in brain-derived microglial cells.  Suppression 
of this Nef-mediated Hck activation by expressing of dominant-negative Hck or CD45 
phosphatase inhibits HIV replication (134). As mentioned above, Hanna et al. showed that 
targeted expression of Nef alone in HIV-1 target cells (T cells and macrophages) in transgenic 
mice results in AIDS-like disease development (101,102). However, mice expressing a mutant 
form of Nef lacking the PxxPxR motif essential for SH3 binding failed to develop this AIDS-like 
phenotype (104). Additionally, Nef-mediated AIDS like disease development is delayed in Hck-
null mice (104). Taken together, these results underscore the importance of Nef-SFK interaction 
in HIV replication and AIDS pathogenesis. 
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Most previous studies investigating the Nef mediated SFK activation, have used 
laboratory alleles such as Nef SF2, NL4-3, and Bru-Lai (35,45,156,226,256). This led us to 
question whether SFK activation, particularly of Hck, was a general function of primary HIV-1 
Nef variants from major clades of HIV-1.   In the present study, we directly evaluated whether 
Hck SH3 domain binding and kinase activation in vitro are indeed properties common to Nef 
alleles representative of all major HIV-1 subtypes. In addition, we used our established yeast-
based kinase assay to evaluate Nef-mediated activation of SFKs in a defined cellular context 
(256,257). The Nef proteins used in this study were derived from all major HIV-1 clades (A, B, 
C, D, F, G, H, J and K) share the conserved PxxPxR motif and hydrophobic pocket residues 
essential for SH3 binding. Using GST pull-down and in vitro kinase assays, we first showed that 
these Nef proteins from primary isolates bind to the Hck SH3 domain and activate recombinant, 
downregulated Hck in vitro. Next, using the system, we showed that all of the primary Nef 
proteins also activated Hck and Lyn (and c-Src to a lesser extent) in cells. However, Nef had no 
detectable effect on other SFKs expressed in HIV-1 target cells, namely Lck, Fyn and Fgr. These 
results support for the first time that Nef-mediated activation of a subset of Src-family kinases is 
broadly conserved among all major HIV-1 clades, validating complexes of Nef with Hck, Lyn 
and c-Src as broad-based targets for anti-HIV drug discovery. 
In related work, we evaluated the effect of AIDS patient-derived Nef alleles on SFK 
activation to determine whether selection occurs for enhanced SFK activation during disease 
progression within a single patient. Previous studies have shown that HIV-1 infects macrophages 
and microglia cells in the brain and about 10-30% of AIDS patients eventually develop HIV-1 
associated dementia (HAD), in which Nef plays an important role (86,261). Remarkably, Nef 
alleles derived from brain showed significant divergence in sequence and function compared to 
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those derived from lymphoid tissues within the same patients suffering from AIDS/HAD 
(7,8,193). This could be due to positive selective pressure for replication capacity of HIV-1 in 
macrophages and microglia cells (86,88). Moreover, Nef expression in macrophages enhances 
HIV-1 replication and results in secretion of cytokines which lead to paracrine activation of T 
cells as well as enhancement of transcription from the viral LTR (165,251,261). Nef alone in the 
absence of other viral proteins is able to induce monocyte/macrophage recruitment, expression of 
TNF-alpha, and astrogliosis as well as cognitive deficits in a murine model (181). Similarly, Hck 
activation in macrophages enhances HIV-1 replication and pathogenesis by enhancing proviral 
transcription. Moreover, Hck activation leads to proliferation of HIV-1 infected microglia and 
dysregulation of the immune response by altering macrophage phagocytosis and chemotaxis 
(65,134,246).  These observations point to a connection between Nef-mediated Hck activation in 
the development of HAD. Previous studies by Gabuzda et al. have shown that nef alleles isolated 
from brain have adaptively evolved to enhance specific Nef functions compare to those isolated 
from peripheral organs from same patients (8,193). In the second part of this study, we evaluated 
the impact of adaptive evolution of nef sequences from four HAD patients on Hck and Fyn T 
activation using our yeast-based kinase assay. These patient-derived Nefs strongly activated Hck, 
but failed to activate Fyn T. Moreover, using a yeast growth suppression assay as well as 
quantitative western blotting we showed that brain-derived Nef positively evolved to activate 
Hck more strongly than Nef from peripheral lymphoid organs within the same patients. This 
study suggests that evolution of HIV-1 associated with HAD involves selection of Nef sequences 
with an enhanced ability to activate Hck.   
The two main analytical methods used in the first part of this study involve the co-
expression of Nef and SFK proteins in a yeast system, as well as an in vitro kinase assay with 
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purified recombinant Nef and SFKs.  Each of these systems, and the rationale for their use, are 
described briefly below. 
 
Yeast-based kinase assay:  We have used a yeast cell-based kinase assay to evaluate the effect 
of primary HIV-1 Nef proteins on the activity of SFKs expressed in HIV-1 target cells. Our 
laboratory has previously shown that yeast is a good model system to study the effect of Nef on 
SFKs due to the absence of intrinsic tyrosine kinases (256,257). Moreover, similar to mammalian 
cells, yeast also provide post-translational modification of expressed proteins such as 
myristoylation of SFKs and HIV-1 Nef (147,256). When ectopically expressed in yeast, SFKs 
phosphorylate endogenous yeast proteins and cause growth suppression (72,219). However, the 
mechanism by which cellular SFK activation in yeast leads to growth suppression is unknown. 
Previous studies reported that activation of v-Src leads to phosphorylation and activation of 
cyclin-dependent kinase Cdc28 that negatively regulates DNA replication during mitosis and 
meiosis and causes growth suppression (72,219). In this way, HIV-1 Nef-mediated activation of 
SFKs can be measured by either evaluating tyrosine phosphorylation of endogenous proteins 
from lysed yeast cells or evaluating growth of yeast cells on solid culture medium. In this way, 
this system allows us to analyze not just the physical binding but the functional consequences of 
Nef-SFK interaction. Moreover, with the help of this system we were able to express 
functionally active full-length SFKs without adding epitope tags in a cellular context free from 
endogenous tyrosine kinases and regulators of SFK activity. Similarly, we were able to evaluate 
the effect of primary nef alleles from all clades on SFK regulation which was not possible using 
the in vitro kinase assay, because some of the Nef proteins could not be produced in soluble 
recombinant form.  In the present study, we used yeast strain Saccharomyces cerevisiae YPH499 
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(Stratagene) and yeast expression plasmids pESC-TRP (Stratagene), pESC-URA (Stratagene) 
and pYC2/CT (Invitrogen). The genes of interest are cloned under the control of GAL promoters 
present in these vectors, so expression is induced only in the absence of glucose and in the 
presence of galactose as the sole carbon source on defined medium. In addition, the SFKs are 
expressed with modified “YEEI” tails so that they adopt the downregulated conformation in the 
absence of the negative regulatory kinase, Csk.  This change simplifies the system while 
avoiding growth suppression when expressed in the absence of Nef or other activating factors.  
Our previously published studies have shown that Nef interacts with Hck in this system through 
an SH3-dependent mechanism previously defined in vitro and in mammalian cells (256,257). 
Thus, yeast provides a well-defined, experimentally tractable and relevant model for rapid 
analysis of Nef interactions with SFKs. 
   
Z’-lyte kinase assay: The Z'-lyte kinase assay (Invitrogen) is a FRET (Fluorescence Resonance 
Energy Transfer)-based assay which employs a coupled-enzyme format and is based on the 
differential sensitivity of phosphorylated and non-phosphorylated peptides to proteolytic 
cleavage (Figure 7).  In the primary reaction, the kinase transfers the gamma-phosphate of ATP 
to a single tyrosine residue in a synthetic FRET-peptide substrate. In the secondary reaction, a 
site-specific protease recognizes and cleaves non-phosphorylated FRET-peptides. Cleavage 
disrupts FRET between the donor (i.e., coumarin) and acceptor (i.e., fluorescein) fluorophores on 
the FRET-peptide, whereas uncleaved, phosphorylated FRET-peptides maintain FRET (63,220).  
Phosphorylation of the FRET-peptides is measured by ratiometric analysis of both fluorescent 
emissions (coumarin 445 nm/FRET 520 nm).  Our previous work has shown that Nef induces 
recombinant Hck-YEEI activation in this system, and that inhibitors of this reaction discovered 
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using this assay have activity against Nef-dependent HIV-1 replication (63,256).  This approach 
provides an important in vitro complement to the yeast assay, as it shows that Nef is sufficient to 
induce kinase activation in the absence of other cellular factors in most cases. Moreover, this in 
vitro assay has an excellent Z-factor (~0.8) which allowed our laboratory to screen more than 
300,000 compounds for inhibition of Nef-mediated Hck activation to date. 
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Figure 7.  Z’-lyte kinase assay principle. 
The kinase transfers the γ-phosphate of ATP to a single tyrosine residue in a synthetic FRET-
peptide substrate (Tyr-2 peptide).  Phosphorylation of the FRET-peptide suppresses cleavage by 
a protease in the Development Reagent. Cleavage disrupts FRET between the coumarin donor 
and fluorescein acceptor fluorophores on the FRET-peptide, whereas uncleaved, phosphorylated 
FRET-peptides maintain FRET.  This is a ratiometric assay, in which kinase activity is reported 
from each well as an emission ratio of coumarin fluorescence to the FRET signal.  In this way, 
the coumarin signal provides an internal standard for substrate concentration and reduces well-
to-well variation (63,220). 
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3.3 MATERIALS AND METHODS 
Yeast and bacterial expression vectors 
Nucleotide sequences encoding representative Nef proteins from each of the HIV-1 M-group 
subtypes (A1, A2, B, C, F1, F2, G, H, J and K) were synthesized commercially (DNA2.0). The 
Nef sequences were PCR amplified and subcloned into the bacterial expression vectors pET14b 
and pET21a (Novagen/EMD Biosciences).  Construction of similar bacterial expression vectors 
for Nef-SF2 (lab allele, B-clade) and Nef-ELI (D-clade) has been described (257).  For yeast 
studies, the Nef sequences from DNA2.0 plasmids were subcloned into the yeast expression 
vectors pESC-Trp or pESC-Trp-Csk under the control of the GAL10 promoter as described 
previously (256). Similar pESC and pYC2/CT-based vectors for yeast expression of Hck, Lyn, 
Lck, Fyn, Fgr, and c-Src as well as the Herpesvirus saimiri Tip protein have been reported 
previously by our group (179,256,257).  
 
Antibodies 
Antibodies used in this study were obtained from the NIH AIDS Research and Reference 
Reagent Program (Nef,  2949), Santa Cruz Biotechnology (pY99, sc-7020; Hck, sc-72; Lyn, sc-
15; Fyn, sc-16; Lck, sc-13; c-Src, sc-18; Csk, sc-286; Fgr, sc-17; His-tag, sc-803; GST, sc-138), 
Sigma-Aldrich (Flag-tag, A2220), and Millipore (actin, MAB 1501). 
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Nef and Hck protein purification 
E. coli BL21 Rosetta (Novagen) or ArcticExpress (Stratagene) strains were transformed with 
pET14b or pET21a Nef expression plasmids and protein expression was induced with 0.5 mM 
IPTG at 28 °C for 4 h (Rosetta) or at 11 °C for 24 h (ArcticExpress).  The bacterial cells were 
collected by centrifugation and lysed by sonication in either His-lysis buffer (20 mM Tris-HCl, 
pH 8.3, 500 mM NaCl, 20 mM imidazole, 10% glycerol and 5 mM β-mercaptoethanol) or Q-
lysis buffer (20 mM Tris-HCl, pH 8.3, 10% glycerol and 5 mM β-mercaptoethanol).  Lysates 
were clarified by centrifugation at 30,000 g at 4 °C for 30 min. His-tagged Nef proteins were 
purified by Ni-NTA affinity chromatography while untagged Nef proteins were purified by anion 
exchange chromatography using an ÄKTAexplorer automated chromatography system in both 
cases (GE Healthcare). Lysates containing His-tagged Nef were loaded on a Ni-NTA HiTrap 
Chelating HP column (5 ml; GE Healthcare) pre-equilibrated with lysis buffer. After washing 
with 2 column volumes (CV) of lysis buffer, proteins were eluted in His-elution buffer (20 mM 
Tris-HCl, pH 8.3, 1 M imidazole, 10% glycerol and 5 mM β-mercaptoethanol) with a linear 
gradient of 20 mM to 1 M imidazole over 6 CV.  Lysates containing untagged Nef were loaded 
onto a HiPrep Q FF 16/10 column (20 ml; GE Healthcare) pre-equilibrated with lysis buffer. 
After washing with 2 CV of lysis buffer, proteins were eluted in Q-elution buffer (20 mM Tris-
HCl, pH 8.3, 1 M NaCl, 10% Glycerol and 5 mM β-mercaptoethanol) using a linear gradient of 0 
to 500 mM NaCl over 3 CV. Both the His- tagged and untagged proteins were further purified by 
gel filtration chromatography on a HiLoad 26/60 Superdex 75 column (GE Healthcare) with 20 
mM Tris-HCl, pH 8.3, 100 mM NaCl and 3 mM DTT as mobile phase.  Recombinant near full-
length Hck kinase was purified in its downregulated conformation from Sf-9 insect cells as 
described in detail elsewhere (63,256).  
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Nef-SH3 domain binding assay 
GST-tagged Hck SH3 domain fusion proteins (wild-type and W93A mutant) as well as GST 
alone were expressed in E. coli BL21 Rosetta cells and immobilized on glutathione-agarose 
beads according to our published protocol (232). For Nef-SH3 binding assays, each recombinant 
purified Nef protein (1 µg) was incubated with an equimolar amount of immobilized GST or the 
GST-SH3 fusion proteins in 500 µl of lysis buffer (50 mM Tris-HCl, pH 7.4, 50 mM NaCl, 10 
mM Mg2Cl, 1 mM EDTA, 1% Triton X-100) supplemented with protease inhibitors at 4 °C for 2 
h.  Binding reactions were then washed by resuspending the beads 4 times in 1 ml RIPA buffer 
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 1% 
sodium deoxycholate) supplemented with protease inhibitors.  Associated Nef proteins were 
eluted in SDS-PAGE sample buffer at 95 °C for 10 min, separated by SDS-PAGE, and 
visualized by immunoblotting with antibodies against the N-terminal His tag. 
 
Surface Plasmon Resonance (SPR) 
For SPR analysis of Hck-YEEI and untagged primary Nef proteins, buffer-exchange and 
concentration was first conducted using HBS-EPD buffer (10 mM HEPES, pH 7.4, 150 mM 
NaCl, 3 mM EDTA, 0.005 % v/v P20 surfactant, 1 mM DTT) and an Amicon Ultra 15 ml 10 
kDa molecular weight cutoff spin concentrator. For SPR studies with the Hck SH3 domain alone, 
proteins were buffer-exchanged and concentrated as above but using HBS-EPD buffer 
containing 0.05% (v/v) P20 surfactant in order to reduce non-specific binding to the biosensor 
chip. SPR analysis was performed on a BIAcore 3000 instrument (GE Healthcare) using a four 
channel CM5 biosensor chip with Hck-YEEI or Hck SH3 covalently attached as ligand via 
standard amine coupling chemistry (185). Nef proteins (as analyte) were flowed past the 
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immobilized Hck proteins on the biosensor chip at a flow rate of 10 µl/min for 5 min using Nef 
protein concentrations above and below the KD (see Table 1). The initial binding reaction was 
followed by dissociation for 5 min, and the chip surface was regenerated using HBS-EPD buffer 
at a flow rate of 30 µl/min for 10 min. Binding curves recorded at each analyte concentration 
were assessed in triplicate, corrected for buffer effects, and fit to either a 1:1 Langmuir binding 
model or a steady-state affinity model using the BIAevaluation 4.1 software suite (GE 
Healthcare). 
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Table 1. Concentrations of recombinant HIV-1 Nef proteins. 
 
Nef 
Protein 
Nef Type [Nef] used for Hck-YEEI SPR (μM)  [Nef] used for Hck SH3 SPR (μM)  
SF2 
Laboratory 
(B-clade) 
0, 0.062, 0.19, 0.56, 1.67, 5.0, 10.0  
0, 0.007, 0.02, 0.062, 0.19, 0.56, 1.67, 
5.0 
 
Consensus 
Laboratory 
(B-clade) 
0, 0.062, 0.19, 0.56, 1.67, 5.0, 10.0, 
20.0 
 0.02, 0.062, 0.19, 0.56, 1.67, 5.0  
A2 Primary 0, 0.19, 0.56, 1.67, 5.0, 10.0, 20.0, 30.0  
0, 0.062, 0.19, 0.56, 1.67, 5.0, 10.0, 
20.0 
 
B Primary 
0, 0.062, 0.19, 0.56, 1.67, 5.0, 10.0, 
20.0 
 
0, 0.062, 0.19, 0.56, 1.67, 5.0, 10.0, 
20.0 
 
F1 Primary 0, 0.19, 0.56, 1.67, 5.0, 10.0, 20.0, 50.0  
0, 0.062, 0.19, 0.56, 1.67, 5.0, 10.0, 
20.0 
 
F2 Primary 0, 0.19, 0.56, 1.67, 5.0, 10.0, 20.0, 40.0  
0, 0.062, 0.19, 0.56, 1.67, 5.0, 10.0, 
20.0 
 
J Primary 
0, 5.0, 10.0, 20.0, 40.0, 80.0, 100.0, 
160.0 
 0, 5.0, 10.0, 20.0, 60.0  
K Primary 
0, 0.062, 0.19, 0.56, 1.67, 5.0, 10.0, 
20.0 
 0, 0.19, 0.56, 1.67, 5.0, 10.0, 20.0  
 
Concentrations of recombinant HIV-1 Nef proteins used to determine equilibrium dissociation 
constants with Hck-YEEI and the Hck SH3 domain.  SPR analysis was performed with 
recombinant Hck-YEEI or the isolated Hck SH3 domain covalently attached to the biosensor 
chip as described under Materials and Methods.  Untagged, purified Nef proteins were flowed 
past the immobilized Hck proteins at each of the concentrations shown, and binding response 
curves were fit to a 1:1 Langmuir binding model or steady-state affinity model using the 
BIAevaluation 4.1 software suite to determine the equilibrium dissociation constants shown. 
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In vitro kinase assay 
Nef-mediated activation of Hck tyrosine kinase activity was assayed using the Z’-Lyte method 
with the Tyr2 peptide substrate (Invitrogen/Life Technologies).  The principle of this FRET-
based assay is described in detail elsewhere (63,256) and in Figure 7.  Briefly, reactions (10 µl) 
were conducted in 384-well plates. Recombinant Hck (25 ng) was incubated with a 10-fold 
molar excess of each recombinant Nef protein in kinase assay buffer (50 mM Hepes, pH 7.5, 10 
mM MgCl2, and 1 mM EGTA, 0.01% Brij-35) for 1 h at room temperature. For experiments 
with Hck in the absence of Nef, higher input kinase was used (75 ng) to achieve equivalent levels 
of substrate phosphorylation to that observed in the presence of Nef.  Development reagent was 
then added to the reaction for an additional 60 min at room temperature, followed by the stop 
reagent.  Fluorescence was assessed at an excitation wavelength of 400 nm; coumarin 
fluorescence and the fluorescein FRET signal were monitored at 445 and 520 nm, respectively. 
Reactions run in the absence of ATP served as the 0% phosphorylation control, whereas 
stoichiometrically phosphorylated Tyr2 peptide was used as the 100% phosphorylation control. 
Raw fluorescence values were corrected for background, and reaction endpoints calculated as 
emission ratios of coumarin fluorescence divided by the fluorescein FRET signal.  These ratios 
were then normalized to the ratio obtained with the 100% phosphorylation control peptide. Each 
condition was assayed in quadruplicate, and results are presented as the mean ± S.D. 
 
Yeast assay for SFK activation 
The yeast-based assay for analysis of SFK activation by Nef and other viral proteins is described 
in detail elsewhere (168,179,256,257). Briefly, Saccharomyces cerevisiae strain YPH 499 
(Stratagene) was co-transformed with pESC-Ura (or pYC2/CT-Ura) and pESC-Trp plasmids 
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containing the genes of interest via electroporation (Bio-Rad GenePulser II).  Transformed 
colonies were selected on synthetic drop-out medium lacking uracil and tryptophan with glucose 
as sole carbon source for 3 d at 30 °C.  Colonies were cultured in galactose-containing medium 
lacking uracil and tryptophan for 18 h at 30 °C to induce gene expression. Cell densities were 
normalized to an OD600 of 0.2 in water and lysed with 0.1N NaOH for 5 min at room 
temperature. Aliquots of each lysate were separated via SDS-PAGE, transferred to 
polyvinylidene difluoride (PVDF) membranes, and probed for protein phosphotyrosine content 
by immunoblotting with anti-phosphotyrosine antibodies.  Replicate blots were probed for 
expression of each SFK, Nef and actin as a loading control. 
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3.4 RESULTS AND DISCUSSION 
3.4.1 Alignment of Primary Nef Proteins: SFK SH3-binding sequences are highly 
conserved across primary HIV-1 Nef isolates 
One of the major objectives of this study was to address whether SH3 domain-mediated 
activation of SFKs is conserved across primary Nef alleles derived from all M-group clades of 
HIV-1.  To address this question, we assembled a set of Nef cDNA clones representative of all 
major non-recombinant HIV-1 subtypes.  We first queried the NIH HIV-1 sequence database (3) 
to obtain sequences of Nef alleles from patient isolates of HIV-1 clades A1, A2, B, C, D, F1, F2, 
G, H, J and K.  These clades are representative of the major subgroup of HIV-1 strains 
responsible for more than 90% of HIV-1 infections associated with the global HIV/AIDS 
pandemic (111,194,205). Each of these sequences was translated in silico and those that encoded 
truncated Nef proteins were eliminated. Of the remaining sequences, one from each clade was 
aligned together with the laboratory alleles Nef-SF2 (clade B) and Nef-ELI (clade D).  These two 
Nef variants have been studied extensively by our group in terms of Nef-mediated SFK 
activation, and serve as useful controls (45,156,256).  The alignment revealed strong 
conservation of known residues and motifs essential for SFK SH3 domain binding and kinase 
activation, including the PxxPxR motif and the hydrophobic pocket residues F90, W113, and 
Y/F120 (Figure 3.2).   
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SF2                   MGGKWSKRSMGGWSAIRERMRRAEP-------RAEPAADGVGAVSRDLEKHGAITSSNTA 
A1.SE.94              MGSKWSKSSIVGWREVRERLRQTLAAARG-----------VGAVSQDLEKYGAVTSSNVN 
A2.CD.97.97CDKTB48    MGGKWSKRTIVGWPEIRERMRRTPPAAEG-VRPTPPAAEGVGAVSQDLARHGAVTSSNTA 
J.SE.93.SE7887        MGNKWSKS----WPQVRERMRRAP----------APAADGVGAVSQDLAKHGAITSSNTA 
G.FI.93.HH8793        MGGKWSKR---GWPAVRERIRQTP------IRQTPPAAEGVGAVSQDLARHGAITSSNTA 
C.BR.92.92BR025       MGNKWSKCSTVGRPAIRERMR-RAPAAEG-----------VGPASQDSDKYGALTSSSTP 
K.CD.97.EQTB11C       MGGKWSKSSIVGWSTVRERMR-----------KTPPAADGVGAVSQDLDKHGAVTSSNTA 
B.US.86.JRFL          MGGKWSKRSVPGWSTVRERMRRAEPAADRVR-RTEPAAVGVGAVSRDLEKHGAITSSNTA 
ELI (D-clade)         MGGKWSKSSIVGWPAIRERIRRTNP-----------AADGVGAVSRDLEKHGAITSSNTA 
F1.BE.93.VI850        MGGKWSKSSIVGWPAVGERMRQTPT-----------AAEGVGAVSRDLDRRGAITSSNTR 
F2.CM.95.MP257        MGGKWSKSSIVGWPAIRERIR---------------AAEGVGAVSQDLDKRGAITNSNTG 
H.BE.93.VI997         MGGKWSKSSIVGWPAVRERIRRAQP-----------AADGVGAVSRDLDRRGAVTINNTA 
 
                                              PxxPxR            F90           K/R105 
SF2                   ATNADCAWLEAQEEE--EVGFPVRPQVPLRPMTYKAALDISHFLKEKGGLEGLIWSQRRQ 
A1.SE.94              --HPSCAWLEAQE-E-EEVGFPVRPHVPLRPMTYKGALDLSHFLKEKGGLDGLIYSRRRQ 
A2.CD.97.97CDKTB48    ANNPDCAWLEAQE-E-EEVGFPVRPQVPLRAMTYKGAVDLSHFLKEKGGLDGLIYSQRRQ 
J.SE.93.SE7887        ATNADCAWLEAQT-E-EEVGFPVKPQIPLRPMTYKGAVDLSFFLKEKGGLDGLIYSKKRQ 
G.FI.93.HH8793        TNNPDCAWLEAQEED-SEVGFPVRPQVPVRPMTYKAAFDLSFFLKEKGGLDGLIYSKKRQ 
C.BR.92.92BR025       ANNADCAWLEAQQEE-EEVGFPVRPQVPLRPMTYKAVVDLSFFLEEKGGLEGLIYSKKRQ 
K.CD.97.EQTB11C       FNNPDCAWLEAQEDE-D-VGFPVRPQVPLRPMTFKGAFDLGFFLKEKGGLDGLIYSKRRQ 
B.US.86.JRFL          ATNADCAWLEAQEDE--EVGFPVRPQVPLRPMTYKGAVDLSHFLKEKGGLEGLIHSQKRQ 
ELI                   STNADCAWLEAQEES-DEVGFPVRPQVPLRPMTYKEALDLSHFLKEKGGLEGLIWSKKRQ 
F1.BE.93.VI850        TTNPDLAWLEAQEEE-E-VGFPVRPQVPVRPMTYKAAVDLSHFLKEKGGLEGLIYSKKRG 
F2.CM.95.MP257        ATNADLAWLEAQEE--E-VGFPVRPQVPLRPMTYKAALDLSHFLKEKGGLEGLIYSRKRQ 
H.BE.93.VI997         ATNPDVAWLEAQEEA-EEVGFPVRPQVPLRPMTYKAALDLSHFLKEKGGLDGLIYSKKRQ 
 
                           W113     F121 
                          L112Y115  Y120D123  
SF2                   EILDLWIYHTQGYFPDWQNYTPGPGIRYPLTFGWCFKLVPVEPEKVEEANEGENNSLLHP 
A1.SE.94              EILDLWVYNTQGYFPDWQNYTPGPGVRYPLTFGWCFKLVPVDPDEVEQANEGENNSLLHP 
A2.CD.97.97CDKTB48    DILDLWVYNTQGYFPDWQNYTPGPGARFPLTFGWCFKLVPVDPSEVEEATEGENNSLLHP 
J.SE.93.SE7887        EILDLWVHNTQGYFPDWQNYTPGPGIRYPLTFGWCYKLVPVDPSEVEEANEGENNCLLHP 
G.FI.93.HH8793        DILDLWVYNTQGFFPDWQNYTPGPGTRLPLTFGWCLKLVPVDPAVVEEATTEENNSLLHP 
C.BR.92.92BR025       DILDLWVYNTQGYFPDWQNYTPGPGVRFPLTFGWCFKLVPVDPREVEEANTGENNSLLHP 
K.CD.97.EQTB11C       EILDLWVYHTQGFFPDWQNYTPGPGIRYPLTFGWCYKLVPVDPREVEEATEGENNCLLHP 
B.US.86.JRFL          DILDLWVYHTQGYFPDWQNYTPGPGIRFPLTFGWCFKLVPVEPEKVEEANEGENNCLLHP 
ELI                   EILDLWVYNTQGIFPDWQNYTPGPGIRYPLTFGWCYELVPVDPQEVEEDTEGETNSLLHP 
F1.BE.93.VI850        DTLDLWVYHTQGYFPDWQNYTPGPGIRYPLTLGWCFKLVPVDPEEVEKANEGENNCLLHP 
F2.CM.95.MP257        EILDLWVYHTQGYFPDWQNYTPGPGPRFPLTFGWCFKLVPVDPEEVEKANEGENNCLLHP 
H.BE.93.VI997         EILDLWVYNTQGYFPDWQNYTPGPGEGYPLTFGWCFKLIPVDPQEVERANEGENNCLLYP 
 
 
SF2                   MSLHGMEDAEKEVLVWRFDSKLAFHHMARELHPEYYKDC- 
A1.SE.94              MCQHGMDDEEKETLRWRFDSRLALRHRAQEMHPEFYKDC- 
A2.CD.97.97CDKTB48    ICQHGAEDPEREVLKWKFDSRLALRHLAREQHPEFYKDC- 
J.SE.93.SE7887        ICQHGIEDEEREVLQWKFDSSLARRHIARELHPEFYKDC- 
G.FI.93.HH8793        IWQHGMEDEDREVLIWRFDSSLARRHLARELHPEFYKNC- 
C.BR.92.92BR025       MSLHGMEDSHREVLQWKFDSLLARRHMARELHPEYYKDC- 
K.CD.97.EQTB11C       VNQHGMEDEHREVLKWKFDSSLARKHVAREMHPEYYKD-- 
B.US.86.JRFL          MSQHGIEDPEKEVLEWRFDSKLAFHHVARELHPEYYKDC- 
ELI                   ICQHGMEDPERQVLKWRFNSRLAFEHKAREMHPEFYKN-- 
F1.BE.93.VI850        MSQHGMEDEDREVLRWKFDSSLALRHIARERHPEFYQD-- 
F2.CM.95.MP257        MSLHGMEDDDKEVLKWQFDSRLALRHIARERHPEYYKD-- 
H.BE.93.VI997         ICQHGMEDEEGEVLMWKFDSRLAFTHTAREKHPEFYKDC- 
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Figure 8. Sequence alignment of primary and laboratory Nef alleles used in this study. 
Nef cDNA clones representative of all major non-recombinant HIV-1 clades were selected from 
the NIH HIV-1 sequence database. The sequences with truncated Nef proteins were eliminated 
and representative sequences, one from each clade, were chosen and aligned. The first letter in 
each clone ID indicates the subgroup assignment.  This Clustal W alignment also includes Nef-
SF2 (top), which has been studied extensively in terms of Hck activation, as well as Nef-ELI, 
which fails to activate Hck or other SFKs.  Key residues in the SF2 sequence that are essential 
for SH3 binding are shown in red, and include the PxxPxR motif and hydrophobic pocket 
residues F90, W113, and Y120.  Key residues involved in Nef dimerization interface include 
K/R105, L112, Y115, F121, and D123 and are shown in blue.  
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Figure 9. Structurral features of the Nef: SH3 and Nef dimerization interfaces. 
A) Overview of the Nef:SH3 dimer X-ray crystal structure, which is modeled on the crystal 
coordinates of Lee et al. [PDB: 1EFN; (155)]. The monomeric Nef subunits are modeled in blue 
and green respectively; the SH3 domains are shown in red.  B) Close-up view of the Nef:SH3 
interface. Nef residues P72 and P75 define a polyproline type II helix that meshes with the 
hydrophobic grooves of the SH3 surface, and is oriented and stabilized by an ionic interaction 
between Nef R77 and SH3 D100.  High affinity interaction also requires a hydrophobic pocket 
formed in part by Nef residues F90, W113, and Y120.  This pocket engages SH3 domain RT 
loop I96 (Van der Waals surface shown as dots).  Mutagenesis of either Nef Y120 or SH3 I96 is 
sufficient to disrupt Nef:SH3 interaction (45,154). C) Close-up view of the Nef dimerization 
interface.  Dimer packing involves hydrophobic interactions of side chains of the αB helices 
(L112, Y115, F121) which are orthogonally opposed. This hydrophobic core is capped on both 
ends by ionic interactions involving D123 and R105. 
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A model of the contributions of each of these residues to the Nef:SH3 interface, based on the 
crystal structure of Lee et al., is shown in Figure 9 (155).  Note that while substitution of Y120 
with isoleucine in Nef-ELI (clade D) prevents it from binding and activating Hck in vitro and in 
vivo (45), alignments of a larger group of primary Nef D-clade alleles revealed that this 
substitution is quite rare (data not shown).  In addition to the SH3 domain binding site, there is 
also strong conservation of residues that form the Nef dimerization interface (K/R105, L112, 
Y115, F121, and D123).  Dimerization is critical to many Nef functions, including support of 
HIV-1 replication and SFK activation (209,268,287).  Figure 9 shows a model of Nef:SH3 
dimers, as well as close-up views of the Nef:SH3 and Nef:Nef interfaces. 
3.4.2 Recombinant Nef proteins representative of the HIV-1 major clades bind to the Hck 
SH3 domain 
To evaluate the functional properties of our M-group HIV-1 Nef clade set, we first expressed the 
recombinant Nef proteins in E. coli and purified them to homogeneity.  As shown in Figure 10 
A, most of these primary Nef sequences yielded soluble recombinant proteins, with the 
exceptions of Nef-C and Nef-H.  All of the recombinant Nef proteins eluted as single 
symmetrical peaks by gel filtration, and their molecular weights were confirmed by mass 
spectrometry (data not shown). 
 We first evaluated the binding of purified Nef proteins to the Hck SH3 domain.  Because 
SH3 interaction requires the proper three-dimensional fold of the Nef core (96,155), these studies 
provided an assessment of whether our recombinant purified Nef proteins folded correctly in 
bacteria.  The wild-type Hck SH3 domain, as well as a mutant known to be defective in SH3 
binding [W93A; (232)], were expressed in bacteria as GST fusion proteins and purified using 
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glutathione-agarose beads. Wild-type GST-SH3, the GST-SH3-W93A mutant control, as well as 
GST alone were incubated with purified recombinant Nef proteins, followed by extensive 
washing.  Bound Nef was then visualized by immunoblot analysis.  As shown in Figure 10 B, all 
primary Nef proteins showed robust binding to the wild-type Hck SH3 domain, while no binding 
was observed with the W93A mutant or with GST alone.  As an additional control, we also 
prepared recombinant Nef-ELI, the rare D-clade allele that lacks the hydrophobic pocket residue 
Y120 and thus fails to activate Hck (256).  As expected, Nef-ELI failed to bind to the Hck SH3 
domain in this assay.  Taken together, these data show that Hck SH3 domain binding is a 
conserved property of Nef proteins derived from M-group HIV-1 isolates. 
While the results shown in Figure 10B establish the potential for Nef: SH3 interaction in 
vitro, they do not provide information about the binding affinity of this crucial interaction for the 
SH3 domain or in the context of the full-length kinase. To pursue this question in more detail, we 
turned to surface plasmon resonance analysis. For these studies, either recombinant 
downregulated near full-length Hck (Hck-YEEI) or the isolated Hck SH3 domain was 
immobilized on the biosensor chip. Recombinant Nef proteins were flowed over the chip using a 
range of concentrations, and the resulting sensorgrams were analyzed to determine the 
dissociation constants for each Nef isoform. As shown in Table 2, the interactions of Hck-YEEI 
with the laboratory Nef proteins Nef-SF2 and Nef-Consensus were the strongest, with KD values 
of 0.80 µM and 1.77 µM, respectively. The primary Nef proteins also yielded KD values with 
Hck-YEEI in the low micromolar range, with the exception of Nef-J (KD = 108.60 µM). The KD 
values for Nef interaction with the isolated Hck SH3 domain were somewhat more variable, with 
Nef-SF2 showing the highest affinity (KD = 0.07 µM) and primary Nef-A2 the lowest (KD = 
21.10 µM). Interestingly, for six of the eight Nef proteins tested, the ratios of the KD values for 
  67 
near full-length Hck versus the isolated SH3 domain were greater than one, suggesting that in 
most cases Nef must compete with the regulatory intramolecular SH3-linker interaction within 
Hck in order to bind. However, in the case of Nef-A2 and Nef-F1, this ratio was less than one, 
raising the interesting possibility that additional Nef: Hck contacts may contribute to 
destabilization of the Hck SH3: linker interaction required for activation in some cases. 
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Figure 10. Purified primary Nef proteins bind to the Hck SH3 domain. 
A) SDS-PAGE of recombinant purified Nef proteins.  Each of the indicated Nef subtypes was 
expressed in bacteria and purified either with N-terminal His-tags (left) or left untagged (center) 
as described in the text.  The untagged Nef proteins were used for SPR experiments (see Table 
2).  GST and GST fusion proteins with the Hck SH3 domain (wild-type and W93A mutant) were 
also expressed in bacteria and immobilized on glutathione-agarose beads (right).  Aliquots of 
each protein were resolved on 15% SDS-PAGE and stained with Coomassie blue. B) Nef-SH3 
binding assay. Recombinant His-tagged Nef proteins (1 µg) were incubated with equimolar 
amounts of immobilized GST and GST-SH3 fusion proteins. The agarose beads were then 
washed, and associated Nef proteins were detected by immunoblotting using antibodies to the 
His-tags. 
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Table 2. Evaluation of Nef binding to Hck-YEEI by Surface Plasmon Resonance (SPR). 
Nef protein Nef type Hck-YEEI, KD 
(μM) 
Hck SH3, KD 
(μM) 
YEEI/SH3 KD 
ratio 
SF2 
 
 
 
Laboratory (B-clade) 0.80 ± 0.15  0.07 ± 0.01  11.43 
Consensus Laboratory (B-clade*) 1.77 ± 0.04  0.12 ± 0.01  14.75 
A2 Primary 12.80 ± 1.64 21.10 ± 1.41  0.61 
B Primary 6.05 ± 0.78 3.82 ± 0.10 1.58 
F1 Primary 2.77 ± 0.70 3.41 ± 0.16 0.81 
F2 Primary 4.71 ± 0.44 1.31 ± 0.42 3.60 
J Primary 108.60 ± 8.80 13.41 ± 3.10 8.10 
K Primary 11.90 ± 2.68 3.93 ± 0.09  3.03 
 
SPR analyses were performed with recombinant purified Hck-YEEI or the isolated Hck SH3 
domain covalently attached to the biosensor chip, as described under Materials and Methods.  
The analyte in the mobile phase was the untagged, purified Nef protein while the ligand 
immobilized on the surface was the Hck protein (Hck-YEEI or SH3 alone).  Each Nef protein 
was serially injected and interaction monitored over a range of Nef concentrations as shown in 
Table 1. The kinetics and affinities of binding were calculated by fitting the data to a 1:1 
Langmuir binding model or, for interactions exhibiting fast rates of association, the 
measurements were repeated under steady-state conditions.  The dissociation constants shown 
were generated using the BIAevaluation 4.1 software suite.  These data were produced in 
collaboration with John Jeff Alvarado, Haibin Shi, and Joanne Yeh, Department of Structural 
Biology, University of Pittsburgh School of Medicine. 
*Consensus Nef is based on a sequence alignment of multiple B-clade Nef proteins (238). 
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3.4.3 Recombinant Nef proteins representative of the HIV-1 major clades activate the 
Hck in vitro 
Previous studies have established that Nef activates Hck (and other Src-family members) through 
displacement of the SH3 domain from its regulatory interaction with the SH2-kinase linker 
(180,256).  Thus, Nef must have sufficient binding affinity to compete for the internal SH3-
linker interaction present in the downregulated form of Src-family kinases (64).  To determine 
whether the SH3-binding activity of our primary Nef proteins was sufficient to induce Hck 
activation, we turned to the FRET-based Z’-Lyte kinase assay which we have used previously to 
demonstrate Nef-mediated Hck activation in vitro (see section 3.2). Purified, downregulated Hck 
(Hck-YEEI) was incubated in the absence or presence of a 10-fold molar excess of each Nef 
protein prior to assay.  As shown in Figure 11, all of the primary Nef proteins activated Hck in 
the Z’-Lyte assay, demonstrating for the first time that Hck activation is a highly conserved 
property of M-group Nef alleles despite some variation in the affinity of the individual Nef 
proteins for the Hck SH3 domain. 
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Figure 11. Purified primary Nef proteins activate downregulated Hck in vitro. 
Recombinant downregulated Hck [Hck-YEEI; (63,256,257)] kinase activity was determined in 
the absence or presence of the indicated Nef proteins using the Z-Lyte assay as described in the 
text.  Results are expressed as the mean percent of maximum substrate phosphorylation ± S.D.; 
this experiment was repeated twice with comparable results. 
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3.4.4 HIV-1 Nef proteins from all major clades strongly activate Hck, Lyn and c-Src in a 
cell-based assay 
Studies with recombinant Nef proteins derived from primary HIV-1 sequences all exhibited 
SH3-binding and Hck activation (Table 2 and Figure 10B and 11).  However, we were not able 
to assess the activity of Nef-C and Nef-H, because soluble recombinant proteins could not be 
obtained from these sequences.  To assess the interaction of these Nef proteins with Hck, and to 
expand our study to other members of the Src kinase family in a cell-based assay, we turned to a 
yeast system previously developed by our group (256,257).  In this assay, Hck and other Src-
family kinases are expressed with modified “YEEI” tails so that they adopt the downregulated 
conformation in the absence of the negative regulatory kinase, Csk.  This point is important 
because active Src-family kinases cause growth arrest in yeast (256).  
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Figure 12. Expression of Nef alone or Nef with Csk has no effect on phosphorylation of 
yeast proteins. 
 
Yeast (S. cerevisiae) strain YPH499 was co-transformed with Nef expression plasmids either 
alone (A) or in the presence of Csk (B). Colonies were selected on synthetic drop-out (SD) 
medium in the absence of uracil and tryptophan (-Ura/-Trp) with dextrose as sole carbon source 
at 30
0
 C. Colonies were picked and expanded in liquid SD -Ura/-Trp medium plus dextrose to 
suppress Nef and SFK expression. Protein expression was induced by transferring the cultures to 
galactose-containing SD -Ura/-Trp medium for 16 h at 30°C. Yeast lysates were analyzed for 
phosphorylation of yeast proteins by anti-phosphotyrosine immunoblotting (pTyr). Co-
expression of Nef-SF2 with Hck-YEEI (A) and active c-Src (B) served as positive controls for 
phosphorylation of yeast proteins. Note that none of Nef alleles alone or in presence of Csk have 
any effect on phosphorylation of yeast proteins. 
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Before evaluating the effect of the primary Nef protein expression on SFK activity in 
yeast, we first performed control experiments to determine whether Nef alone (or Nef with the 
SFK regulator, Csk) had any effect on tyrosine phosphorylation of yeast proteins.  Yeast cultures 
expressing each primary Nef protein as well as Nef-SF2 and Nef-ELI were grown in defined 
medium with galactose as the sole carbon source to induce gene expression. Yeast protein-
tyrosine phosphorylation was evaluated by immunoblotting of yeast cell lysates.  As shown in 
Figure 12, none of the Nef proteins induced tyrosine phosphorylation in the absence of a co-
expressed SFK.  Co-expression of Nef-SF2 with Hck is included as a positive control.  Co-
expression of Nef with Csk, the negative regulator of SFKs, also did not induce yeast protein-
tyrosine phosphorylation (Figure 12).  In contrast, expression of c-Src (in the absence of Csk) led 
to strong tyrosine phosphorylation of yeast proteins.  These results indicate that expression of 
Nef alone or Nef with Csk does not induce tyrosine phosphorylation signals, consistent with the 
lack of endogenous SFK orthologs in yeast. 
 To assess primary Nef-induced SFK activation in this system, yeast cultures were co-
transformed with expression plasmids for each primary Nef sequence and Src family member, 
and colonies were selected on glucose agar to repress protein expression from the Gal promoter.  
Transformed colonies were then grown in liquid medium with galactose as sole carbon source to 
induce Nef and SFK expression.  The cultures were lysed, and SFK activation was evaluated by 
immunoblotting with anti-phosphotyrosine antibodies. Nef-SF2 and Nef-ELI served as positive 
and negative controls, respectively.  As shown in Figure 13, Nef-SF2 strongly activated Hck 
while Nef- ELI failed to do so, consistent with our previous data (256). All of the primary nef 
alleles tested also induced dramatic Hck activation, as reflected by the strong phosphorylation of 
yeast cell proteins in comparison to downregulated Hck-YEEI alone.  Similar results were 
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obtained with Lyn, although tyrosine phosphorylation of yeast cell proteins was less extensive 
for this Src family member and may reflect more stringent substrate protein selection relative to 
Hck.  Interestingly, Lyn also appeared to strongly phosphorylate selective Nef isoforms, 
including A2, B, C, F2, G, H, and K, as well as SF2 (Figure 14).  This observation raises the 
possibility that tyrosine phosphorylation of Nef may influence its function or interaction with 
other binding partners.  
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Figure 13. Primary M-group HIV-1 Nef proteins strongly activate Hck in cells. 
Yeast cultures were transformed with a galactose-inducible expression plasmid for Hck-YEEI, 
which carries a modified C-terminal tail that enables downregulation in the absence of Csk 
(257), or the empty expression plasmid as a negative control (Con).  Where indicated, Hck-YEEI 
cells were co-transformed with galactose-inducible vectors for Nef-ELI, Nef-SF2, and 10 
primary nef alleles (A1, A2, B, C, F1, F2, G, H, J, and K).  Transformed cells were grown in 
liquid culture in the presence of galactose at 30 °C for 18 h. Protein extracts were separated via 
SDS-PAGE and immunoblotted for tyrosine-phosphorylated proteins (pTyr) as well as for Nef, 
Hck and actin as a loading control.  Nef-ELI is unable to interact with Hck and serves as an 
additional negative control (257).  This experiment was repeated three times with comparable 
results. 
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Figure 14. Primary M-group HIV-1 Nef proteins strongly activate Lyn in cells. 
Yeast cultures were transformed with a galactose-inducible expression plasmid for Lyn-YEEI, 
which carries a modified C-terminal tail that enables downregulation in the absence of Csk 
(257), or the empty expression plasmid as a negative control (Con).  Where indicated, Lyn-YEEI 
cells were co-transformed with galactose-inducible vectors for Nef-ELI, Nef-SF2, and 10 
primary Nef alleles (A1, A2, B, C, F1, F2, G, H, J, and K). Transformed cells were grown in 
liquid culture in the presence of galactose at 30 °C for 18 h. Protein extracts were separated via 
SDS-PAGE and immunoblotted for tyrosine-phosphorylated proteins (pTyr) as well as for Nef, 
Lyn and actin as a loading control.  Nef-ELI is unable to interact with Lyn and serves as an 
additional negative control (257).  This experiment was repeated three times with comparable 
results. 
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Figure 15. Primary M-group HIV-1 Nef proteins induce modest activation of c-Src in cells. 
Yeast cultures were transformed with galactose-inducible expression plasmids for c-Src, Csk, 
and the indicated Nef alleles (ELI, SF2, A1, A2, B, C, F1, F2, G, H, J, and K).  Transformed 
cells were grown in liquid culture in the presence of galactose at 30 °C for 18 h. Protein extracts 
were separated via SDS-PAGE and immunoblotted for tyrosine-phosphorylated proteins (pTyr) 
as well as for Nef, Csk, c-Src and actin as a loading control.  
  79 
In addition to Hck and Lyn, we also evaluated the effect of the primary Nef alleles on c-
Src. In case of c-Src, unlike the other SFKs used in the yeast studies, modification of c-Src tail 
with a YEEI tail did not result in effective downregulation in the absence of Csk.  Therefore we 
decided to downregulate c-Src by co-expression of Csk as described previously (256). Yeast 
cultures were co-transformed with c-Src, Csk, and Nef expression plasmids, and protein 
expression was induced in galactose medium as described under Materials and Methods.  
Protein-tyrosine phosphorylation was then evaluated by anti-phosphotyrosine immunoblotting.  
Expression of c-Src alone induced strong phosphorylation of yeast proteins that was 
downregulated in the presence of Csk.  As shown in Figure 15, co-expression of Nef-SF2 
overcame Csk-mediated c-Src inhibition, while Nef-ELI failed to activate c-Src, consistent with 
our previous report (256). Similarly, all of the primary Nef proteins also activated Csk-
downregulated c-Src kinase, albeit to a lesser extent compared to Nef-SF2. 
To look for additional evidence of Nef-mediated c-Src activation, we also monitored 
yeast cell growth. Previous work has shown that ectopic expression of active SFKs induces 
growth arrest in yeast, providing another measure of Nef-SFK interaction in this system 
(157,256,257).  For these experiments, aliquots of each transformed yeast culture shown were 
spotted over a series of dilutions on galactose-agar plates, and the yeast patches appear as dark 
circles in the resulting scanned images of the plates.  Expression of c-Src alone induced growth 
suppression compared to control cultures, while expression of c-Src with Csk reversed this 
effect.  As shown in Figure 16, and consistent with our previous work, expression of Nef-SF2 
overcame the inhibition of c-Src by Csk, leading to growth suppression, while the non-
interacting allele Nef-ELI failed to do so (256). Co-expression of primary Nef proteins with c-
Src also induced growth suppression in the presence of Csk, with the exceptions of Nef-F2 and 
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Nef-H.  These data provide additional evidence that primary Nef proteins from almost all major 
HIV-1 clades activate c-Src in this system.  To control for culture plating density, replicate 
dilutions of each culture were also spotted on glucose-agar plates.  Because glucose represses 
protein expression from the GAL promoter, c-Src, Csk, and Nef are not expressed and all 
cultures grow to the same extent. 
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Figure 16. Primary M-group HIV-1 Nef proteins induce modest activation of c-Src in cells: 
Growth reversion assay. 
 
Yeast cultures as in Figure 15 were grown in SD (-Ura/-Trp) medium containing dextrose as the 
sole carbon source to repress protein expression and normalized to equal densities. Cells were 
then spotted onto agar plates containing galactose as the sole carbon source and incubated for 3 
days at 30 °C to induce gene expression. Cultures were spotted in 4-fold dilutions to enhance 
visualization of the growth-suppressive phenotype. Plates were scanned, and yeast patches 
appear as dark circles. Note that expression of active c-Src causes the growth inhibition. This 
experiment was repeated three times with comparable results. 
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3.4.5 HIV-1 Nef proteins from all major clades failed to activate Lck, Fyn and Fgr in a 
cell-based assay 
We next examined whether primary Nef proteins can activate other SFKs expressed in HIV-1 
target cells using the yeast assay.  Primary Nef proteins were co-expressed with the down-
regulated (YEEI) forms of Lck, Fyn and Fgr, followed by anti-phosphotyrosine immunoblotting 
of yeast cell lysates. As shown in Figure 17, co-expression with Nef had no effect on Lck, Fyn or 
Fgr despite strong expression of the Nef proteins and each SFK.  As a positive control, we co-
expressed Lck-YEEI with the herpesvirus Tip protein, which led to strong Lck activation as 
observed previously (179).  Fyn and Fgr were also expressed as their wild-type forms; in the 
absence of Csk, these SFKs induced strong yeast tyrosine phosphorylation as observed 
previously (256).  
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Figure 17. Primary M-group HIV-1 Nef proteins do not activate Lck, Fyn or Fgr in cells. 
Yeast cultures were transformed with a galactose-inducible expression plasmid for Lck-YEEI, 
Fyn-YEEI, Fgr-YEEI, which carries a modified C-terminal tail that enables downregulation in 
the absence of Csk (257), or the empty expression plasmid as a negative control (Con).  Where 
indicated, these cells were co-transformed with galactose-inducible vectors for Nef-ELI, Nef-
SF2, and 10 primary nef alleles (A1, A2, B, C, F1, F2, G, H, J, and K).  Transformed cells were 
grown in liquid culture in the presence of galactose at 30 °C for 18 h. Protein extracts were 
separated via SDS-PAGE and immunoblotted for tyrosine-phosphorylated proteins (pTyr) as 
well as for Nef, Tip, Lck, mFgr and actin as a loading control. Wild-type Fyn, mFgr and co-
expression of Tip with Lck YEEI served as positive control for respective kinase activation. This 
experiment was repeated three times with comparable results. 
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3.4.6 Alignment of patient-derived Nef proteins 
We next evaluated the effect of divergent evolution of the nef gene in HIV-1 isolates from brain 
versus lymphoid organs from same patient on SFK (Hck and Fyn T) activation.  For these 
studies, full-length nef sequences were amplified from genomic DNA from autopsy brain and 
lymphoid organs from four AIDS patients suffering with HAD (7,8,193). The predicted Nef 
amino acid sequences were determined and the alignment is shown in Figure 8, together with the 
sequence of the laboratory allele Nef-SF2.  The alignment revealed strong conservation of 
known residues and motifs essential for SFK SH3 domain binding and kinase activation, 
including the PxxPxR motif and the hydrophobic pocket residues F90, W113, and Y/F120 
(Figure 8). In addition to the SH3 domain binding site, there is also strong conservation of 
residues that form the Nef dimerization interface (K/R105, L112, Y115, F121, and D123).  
Dimerization is critical to many Nef functions, including support of HIV-1 replication and SFK 
activation (209,268,287). 
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 Nef-SF2 M G G K W S K C S L G G W P A I R E R M R - - - - R A E P A A D - - - - G V G A A S R D L E K H G A L T N S N T V T N N 
                                                              
MACS1 
BR-8a  M G G K W S K C S L G G W P A I R E R M R - - - - R A E P A A D - - - - G V G A A S R D L E K H G A L T N S N T V T N N 
SP-45a    M G G K W S K S S S V G W P A I R E R M R - - - - R A E P A A D - - - - G V G A A S R D L E K H G A L T S S N T V T N N 
                                                              
MACS3 
BR-16n    M G G K W S K C S V G G W S A V R E R M R - - - - R A E P A T E P A A A G V G A V S R D L E K H G A I T S S N T P A T N 
BR-16p    M G G K W S K C S V G G W S A V R E R M K - - - - R A E P A T E P A A A G V G A V S Q D L E K H G A I T S S N T P A T N 
LN-17a  M G G K W S K C G L G G W S A V R E R M R - - - - R A E P A T E P A A A G V G A V S R D L E K H G A I T S S N T P A T N 
                                                              
MACS2 
BR-14c    M G G K W S K S S V V G W P T V R E R M R - - - - R A E P A A D G - - - - V G A A S R D L E R H G A I T S S N T A A N N 
LN-5c  M G G K W S K R S R D G W A S V R E R M R Q A E P R A E P A A E G - - - - V G P A S R D L E R H G A I T S S N T A A N N 
                                                              
UK6 
BR-4a  M G G K W S K S S M I G W P T V R E R M R - - - - R A E P A A D G V - - - V G A V S R D L E K H G A I T S S N T A A N N 
SP-5a  M G G K W S K S S K I G W S T V R E R M R - - - - Q A E P A A D G - - - - V G A V S R D L A R H G A I T S S N T A A T N 
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SP-45a  A A C A W L E A Q E E E E - V G F P V R P Q V P L R P M T Y K A T V D L S H F L K E K G G L E G L I H S Q R R Q D I L D 
                                                              
MACS3 
BR-16n A D C A W L E A Q E K E E - V G F P V R P Q V P L R P M I Y K A A L D I S H F L K E K G G L E G L I Y S Q R R Q D I L D 
BR-16p A N C A W L E A Q E E E E - V G F P V R P Q V P L R P M T Y K A A L D I S H F L K E K G G L E G L I Y S Q R R Q D I L D 
LN-17a A D C A W L E A Q E E E E E V G F P V R P Q V P L R P M T Y K A A L D M S H L L K D K G G L E G L I Y S K K R Q E I L D 
                                                              
MACS2 
BR-14c A T L A W L E A Q K E E E - V G F P V R P Q V P L R P M T Y K G A F D L S H F L K E K G G L E G L I Y S Q R R Q D I L D 
LN-5c A T L A W L E A Q E E E E E V G F P V R P Q V P L R P M T Y K G A F D L S F F L K E K G G L E G L I W S Q K R Q D I L D 
                                                              
UK6 
BR-4a A D C A W L E A H E D E E - V G F P V R P Q V P L R P M T H R A A I D L S H F L R K E G G L E G L I Y S Q R R Q D I L D 
SP-5a A D C A W L E A H E D E E - V G F P V R P Q V P L R P M T H R A A I D L S H F L R K E G G L E G L V Y S Q R R Q D I L D 
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UK6 
BR-4a  L W I Y H T Q G Y F P D W Q N Y T P G P G T R Y P L T F G W C F K L V P V E P E K V E E A N E G E N N S L L H P M S L H 
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MACS1 
BR-8a G M E D S E R E V L V W K F D S R L A F H H M A R E K Y P E Y Y K N C
                         
SP-45a G M E D S E R E V L V W K F D S L L A F H H M A R E K Y P E Y Y K N C 
                         
                                                              
MACS3 
BR-16n G M E D P E G E V L M W K F D S R L A F H H M A R E K H P E F Y K D C
                         
BR-16p G M E D P E G E V L M W K F D S R L A F H H M A R E K H P E F Y K D C 
                         
LN-17a G M E D P E K E V L M W K F D S R L A F H H M A R E K H P E F Y K D C 
                         
                                                              
MACS2 
BR-14c G M E D P E R E V L V W K F D S R L A F H H M A R E K H P E Y F K N C
                         
LN-5c G M D D P E K E V L V W K F D I H L A H H H I A R E K H P E Y F K N C 
                         
                                                              
UK6 
BR-4a G M E D P E K E V L V W K F D S L L A F Q H V A R E L H P E Y Y K D C
                         
SP-5a G M D D P E K E V L V W K F D S T L A H Q H V A R E L H P E F Y K D C 
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Figure 18. Sequence alignment of patient-derived Nef alleles. 
The Nef amino acid sequences shown were derived from four AIDS patients, designated 
MACS1, MACS2, MACS3, and UK6. The corresponding cDNAs were isolated directly from 
patient autopsy brains (BR), lymph nodes (LN), and spleens (SP), with the exception of MACS2 
LN-5C, which was cloned from a lymph node primary viral isolate.  Cloning and tissue origins 
of these Nef alleles and their functional characteristics are described in detail elsewhere 
(7,8,193). The sequence of the laboratory allele Nef-SF2 is included at the top for reference.  
Residues in the Nef-SF2 sequence essential for SH3 binding are shown in red, and include the 
PxxPxR motif and hydrophobic pocket residues F/L90, W113, and Y120. Conserved residues 
that form the Nef dimerization interface include K/R105, L112, Y115, F121, and D123 and are 
shown in blue.  Positions of amino acid differences between peripheral (LN, SP) and brain-
derived sequences derived from the same patient that may account for enhanced activation of 
Hck are indicated by the arrowheads, with the residues in question highlighted in yellow. 
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3.4.7 Patient-derived Nef alleles differentially activate Hck in a cell-based assay 
To assess patient-derived Nef-induced Hck activation, we used the yeast growth assay. For these 
experiments, yeast cultures were co-transformed with expression plasmids for Nef-SF2, Nef-ELI 
as well as the nine organ-derived Nef sequences from four patients [MACS1 (Br-8a, SP-45a); 
MACS2 (Br-14c, LN-5c); MACS3 (Br-16n, Br-16p, LN-17a); UK6 (Br-4a, SP-5a)].  These Nef 
sequences were expressed with Hck-YEEI, and colonies were selected on glucose agar to repress 
protein expression from the Gal promoter.  As described in section 3.4.4, aliquots of each 
transformed yeast culture were then spotted over a series of dilutions on galactose-agar plates to 
induce protein expression, and the yeast patches appear as dark circles in the resulting scanned 
images of the plates. As shown in Figure 19 A, expression of downregulated Hck alone, as well 
as the patient-derived Nef alleles in the absence of Hck, did not affect yeast growth. Co-
expression Nef-SF2 with Hck-YEEI resulted in strong growth suppression while the non-
interacting allele Nef-ELI failed to do so (256). Similar to Nef-SF2, co-expression of all nine 
patient-derived Nef alleles with Hck-YEEI resulted in strong growth suppression (Figure 19 B). 
Surprisingly, the extent of growth suppression, which is directly related to Hck activation, was 
different for Nef proteins from the same patients. In three out of four patients (MACS1, MACS3 
and UK6), the brain-derived Nef proteins showed enhanced Hck activation compare to lymph 
node or spleen-derived Nef within same patient.   
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Figure 19. Enhanced activation of Hck by brain-derived versus peripheral HIV-1 Nef 
proteins from the same patient: Growth reversion assay. 
 
Yeast cultures were transformed either with a galactose-inducible expression plasmid for Nef 
alone (A) or in the presence of Hck-YEEI (B), which carries a modified C-terminal tail that 
enables downregulation in the absence of Csk (257), or the empty expression plasmid as a 
negative control (Con).  Where indicated, Hck-YEEI cells were co-transformed with galactose-
inducible expression vectors for Nef-ELI, Nef-SF2, and nine patient-derived Nef alleles 
[MACS1 (Br-8a, SP-45a); MACS2 (Br-14c, LN-5c); MACS3 (Br-16n, Br-16p, LN-17a); UK6 
(Br-4a, SP-5a)].  Transformed cells were grown in liquid culture in SD (-Ura/-Trp) medium 
containing dextrose as the sole carbon source to repress protein expression and normalized to 
equal densities. Cells were then spotted onto agar plates containing galactose as the sole carbon 
source and incubated for 3 days at 30 °C to induce gene expression. Cultures were spotted in 4-
fold dilutions to enhance visualization of the growth-suppressive phenotype. Plates were 
scanned, and yeast patches appear as dark circles. Note that expression of active Hck causes 
growth inhibition. Nef-ELI is unable to interact with Hck and serves as an additional negative 
control (257).  This experiment was repeated two times with comparable results. 
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To control for culture plating density, replicate dilutions of each culture were also spotted 
on glucose-agar plates.  Because glucose represses protein expression from the GAL promoter, 
Hck-YEEI and Nef are not expressed and all cultures grow to the same extent. 
All of these Nef proteins have the conserved PxxPxR motif as well as the hydrophobic 
pocket residues required for SH3 binding and activation. Comparison of the amino acid 
sequences reveals a few changes that might account for differential Hck activation in brain 
versus peripheral organs (these residues highlighted in yellow in Figure 18). For example, 
spleen-derived Nef from patient MACS1 has a polar Thr84 instead of nonpolar Ala84 just after 
the PxxP motif.  This threonine residue has the potential to form H-binds and may also undergo 
phosphorylation which might hinder interaction with SH3 domain.  In the case of patient 
MACS3, lymph node-derived Nef has Leu90 instead of the critical Phe90 in the hydrophobic 
pocket, while in patient UK6, spleen-derived Nef has a charged histidine residue at this position 
instead of phenylalanine. These mutations seem likely to influence the ability of Nef to bind 
productively to the SH3 domain as required for Hck activation. This hypothesis could be tested 
in future work using SPR with purified primary Nef proteins as described in Section 3.4.2.  In 
addition, Hck and other SFK activation could be validated using either the yeast-based approach 
or Z-lyte assay with the purified proteins.  
To look for additional evidence of enhanced Hck activation by brain-derived patient-
derived nef alleles, transformed colonies were grown in liquid medium with galactose as the sole 
carbon source to induce Nef and Hck expression.  The cultures were lysed, and Hck activation 
was evaluated by immunoblotting with anti-phosphotyrosine antibodies. Nef-SF2 and Nef-ELI 
served as positive and negative controls, respectively.  As shown in Figure 20, Nef-SF2 strongly 
activated Hck while Nef-ELI failed to do so, consistent with our previous data (256).  None of 
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the Nef proteins induced tyrosine phosphorylation in the absence of a co-expressed Hck. All of 
the patient derived Nef alleles tested also induced dramatic Hck activation, as reflected by the 
strong phosphorylation of yeast cell proteins in comparison to downregulated Hck-YEEI alone. 
Similar to yeast growth assay, brain-derived Nef proteins from MACS1 (Br-8a, SP-45a); 
MACS3 (Br-16n, Br-16p, LN-17a) and UK6 (Br-4a, SP-5a) have showed stronger activation of 
Hck than lymph node or spleen-derived Nef. 
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Figure 20. Enhanced activation of Hck by brain-derived versus peripheral HIV-1 Nef 
proteins from the same patients: immunoblot assay. 
 
Yeast cultures were transformed with the expression plasmids described in Figure 19 and grown 
in liquid culture in the presence of galactose at 30 °C for 18 h. Protein extracts were separated 
via SDS-PAGE and immunoblotted for tyrosine-phosphorylated proteins (pTyr) as well as for 
Nef, Hck and actin as a loading control.  Nef-ELI is unable to interact with Hck and serves as an 
additional negative control (257).  This experiment was repeated two times with comparable 
results. 
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Figure 21. Enhanced activation of Hck by brain-derived versus peripheral HIV-1 Nef 
proteins from the same patient: quantitative immunoblot assay. 
 
Yeast cultures were transformed with the expression plasmids described in Figure 19 and grown 
in liquid culture in the presence of galactose at 30 °C for 18 h. Protein extracts were separated 
via SDS-PAGE and immunoblotted for tyrosine-phosphorylated proteins (pTyr) as well as for 
actin as a loading control. The blots were scanned and quantitated for pTyr bands using an 
Odyssey infrared imager (LI-COR Biosciences). This experiment was repeated two times with 
comparable results. 
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Results from the growth suppression assay and antiphosphotyrosine immunoblots provide 
clear evidence of enhanced Hck activation by brain versus peripheral HIV-1 Nef proteins from 
three separate patients. To evaluate this result in a more quantitative way, antiphosphotyrosine 
immunoblots were repeated using an Odyssey infrared imager (LI-COR Biosciences) with 
respect to loading control actin. As shown in Figure 21, the brain-derived Nef proteins from 
patients MACS1, MACS3 and UK6 showed enhanced Hck activation.  Several studies have 
reported the importance of the nef gene in HAD through the activation of macrophages 
(165,192). Our results demonstrate for the first time that the nef gene undergoes evolution in the 
brain to enhance Hck activation. The enhanced Hck activation by brain-derived nef alleles could 
increase HIV-1 replication in brain, inducing dysregulation of macrophages and microglia during 
the progression to HAD. Thus, these results suggest that enhanced Hck activation by Nef 
evolved in brain has role in development of HAD. 
3.4.8 Patient-derived Nef alleles failed to activate Fyn in a cell-based assay 
Previous studies have shown that Nef associates with Fyn in the presence of the TCR ζ chain 
where TCR ζ stabilizes the polyproline type II helix on Nef (13,137). Therefore, we decided to 
explore the evolutionary effect of the specialized organ-derived Nef alleles on Fyn. We 
examined whether patient-derived Nef proteins can activate Fyn T (Fyn T is a Fyn isoform 
specifically expressed in T cells) using the yeast assay. Patient-derived Nef proteins were co-
expressed with the down-regulated (YEEI) forms of Fyn T, followed by anti-phosphotyrosine 
immunoblotting of yeast cell lysates. As shown in Figure 22, co-expression with Nef had no 
effect on Fyn T despite strong expression of the Nef proteins and Fyn T.  Fyn T was also 
expressed as wild-type form; in the absence of Csk, Fyn T induced strong yeast tyrosine 
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phosphorylation as observed previously (256). Though the patient-derived Nef alleles had no 
effect on Fyn T regulation alone, it would be interesting to re-evaluate this interaction in the 
presence of the TCR ζ chain using the yeast-based system. The presence of TCR ζ chain might 
influence Nef-Fyn T interaction. 
(The patient-derived nef alleles used in this study were provided by Kevin Olivieri and 
Dana Gabuzda, Dana-Farber Cancer Institute, Harvard Medical School.) 
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Figure 22. Patient-derived M-group HIV-1 Nef proteins do not activate Fyn T. 
Yeast cultures were transformed with a galactose-inducible expression plasmid for Fyn-YEEI, 
which carries a modified C-terminal tail that enables downregulation in the absence of Csk 
(257), or the empty expression plasmid as a negative control (Con).  Where indicated, Fyn-YEEI 
cells were co-transformed with galactose-inducible vectors for Nef-ELI, Nef-SF2, and nine 
patient-derived Nef alleles [MACS1 (Br-8a, SP-45a); MACS2 (Br-14c, LN-5c); MACS3 (Br-
16n, Br-16p, LN-17a); UK6 (Br-4a, SP-5a)]. Transformed cells were grown in liquid culture in 
the presence of galactose at 30 °C for 18 h. Protein extracts were separated via SDS-PAGE and 
immunoblotted for tyrosine-phosphorylated proteins (pTyr) as well as for Nef, Fyn and actin as a 
loading control. Wild-type Fyn served as positive control for respective kinase activation.  This 
experiment was repeated two times with comparable results. 
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3.5 SIGNIFICANCE AND CONCLUSIONS 
Almost all previous studies of the interaction of HIV-1 Nef with SFKs involved the use of 
laboratory alleles. As these interactions are important in HIV-1 pathogenesis and may represent 
possible therapeutic targets, it was necessary to expand these studies to a larger more 
heterogeneous population of Nef variants derived from the major HIV-1 subtypes responsible for 
the AIDS pandemic. The present study represents the first systematic analysis to address the 
generality of Nef-induced activation of SFKs by employing Nef alleles representative of all 
major HIV-1 clades. Our study demonstrates for the first time that Src-family kinase binding and 
activation are highly conserved properties of HIV-1 Nef isolates representative of all major HIV-
1 subtypes.  As observed previously for Nef proteins derived from laboratory strains of HIV-1 
such as SF2 (45,256), SFK activation is limited to Hck and Lyn, with some activation apparent 
for c-Src.  In contrast, Fyn, Lck, and Fgr, which are also expressed in HIV host cells, do not 
appear to be direct Nef effectors. Furthermore, we extended this observation with patient-derived 
Nef proteins which also strongly activated Hck but had no effect on Fyn T kinase. Furthermore, 
in three of four patients, brain-derived Nef sequences showed enhanced activation of Hck, which 
has previously been implicated in HAD.  These observations support the formation of specific 
Nef-SFK complexes in all HIV target cell types. 
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4.0  NEF ALLELES FROM ALL MAJOR HIV-1 CLADES ENHANCE HIV-1 
REPLICATION IN AN INHIBITOR-SENSITIVE MANNER* 
*Some of the work presented in this chapter has been published in PLoS ONE: 2012 
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4.1 ABSTRACT 
HIV-1 Nef is a 27 kDa myristylated protein expressed early in the HIV-1 replication cycle and is 
essential for high titer viral replication. Because Nef lacks intrinsic enzymatic activity, it exerts 
its effects by interacting with various host cell proteins involved in cellular activation, immune 
recognition and survival. In particular, Nef interacts with the SH3 domain of Hck and other Src-
family protein-tyrosine kinases (SFKs) through its highly conserved proline-rich (PxxPxR) motif 
and hydrophobic pocket.  Nef alone is sufficient to produce AIDS-like symptoms in mice and is 
required for SIV-induced AIDS in monkeys. Moreover, defective or mutated forms of Nef have 
been detected in long term non-progressors patients infected with HIV-1. Nef-induced AIDS-like 
disease was delayed in the absence of Hck kinase in the transgenic mouse model underscoring 
the importance of nef gene in HIV-1 pathogenesis. Our laboratory has shown that HIV-1 Nef 
specifically activates Hck, Lyn and Src. In addition to this, we also showed that this property of 
Nef is highly conserved among all major clades of HIV-1. Recently, our lab identified 4-amino 
substituted diphenylfuranopyrimidines (DFPs) and diphenylpyrazolyldiazene (PPD-B9) that 
selectively inhibit Nef-dependent HIV replication. To determine whether these compounds 
exhibit broad-spectrum Nef inhibition, we first evaluated effects on primary Nef proteins-
mediated Hck activation in in vitro assay. Then to evaluate broad-spectrum Nef-dependent 
antiretroviral activity against HIV-1, we constructed chimeric forms of the HIV-1 strain NL4-3 
expressing the same 10 primary nef alleles. The infectivity and replication of these Nef- chimeric 
HIV-1 was indistinguishable from that of wild-type in three distinct cell lines (MT2, U87MG 
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and CEM-T4). Importantly, the 4-aminopropanol and 4-aminobutanol derivatives of DFP as well 
as PPD-B9 potently inhibited the replication of all 10 chimeric forms of HIV-1 in cell lines 
where HIV-1 replication is Nef-dependent. Moreover, we showed that the inhibition of HIV-1 
replication is due to direct inhibition of HIV-1 Nef-mediated activation of endogenous SFKs in 
CEM-T4 cells. Thus our results validate for the first time that Nef-mediated SFK activation is 
broad-based target for anti-HIV drug discovery. 
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4.2 INTRODUCTION 
HIV-1 Nef is a 27 kDa myristylated protein expressed early in the HIV-1 replication cycle and is 
essential for high titer viral replication (107,136,178,226,245). Nef, an accessory protein only 
present in primate lentiviruses, is not required for HIV-1 replication in vitro but required for high 
titer replication and AIDS pathogenesis in vivo (58,107,132,133,146,178,245,253). Nef is 
required for SIV induced AIDS in monkeys and defective or mutated forms of Nef have been 
detected in long term non-progressors, patients infected with HIV-1 but fail to develop AIDS 
over many years (58,141). 
As detailed in the Introduction, Nef lacks intrinsic enzymatic activity, and interacts with 
many host proteins and exploits cellular signaling pathways to optimize viral replication and 
promote AIDS progression (67,94,127,208,216). One group of key molecular targets for Nef are 
the Src-family kinases (SFKs) which are involved in cellular activation, immune recognition and 
survival (34,35,94,199,216,255,256). As shown in Chapter 3, Nef interacts with and activates a 
subset of SFKs through displacement of regulatory SH3-linker interactions which are required 
for SFK downregulation (35,45,226,256). Moreover, Saksela et al. showed that mutation of the 
PxxP motif of Nef required for SFK SH3 binding significantly hampered Nef-mediated SFK 
activation as well as HIV-1 replication in primary blood cells although there was no effect on 
Nef-mediated CD4 receptor down-regulation (226). Similarly, Nef-mediated activation of Hck is 
required for STAT3 activation and proliferation of myeloid cell line (34). Moreover, Komuro et 
al. showed that suppression of Hck expression with antisense oligonucleotides dramatically 
inhibits M-tropic HIV-1 replication in primary human macrophages (145). In addition, Nef can 
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interrupt macrophage colony-stimulating factor signaling by activating Hck, suggesting that Nef: 
Hck association may contribute to macrophage dysfunction in HIV-infected cells (248).  
The highly conserved nature of Nef-SFK activation and its importance to HIV-1 
replication and pathogenesis has raised interest in this signaling pathway as a therapeutic target.  
In the light of this evidence, our laboratory developed a high-throughput screening assay for 
inhibitors of Nef-mediated Hck activation in vitro as well as yeast-based kinase assay. This effort 
led to the discovery of 4-amino-substituted diphenylfuropyrimidine (DFP), and 
diphenylpyrazolyldiazene (PPD-B9) compounds with low micromolar activity against both Nef-
mediated Hck activation and Nef-dependent HIV-1 replication in cell culture [(63) and L. Emert-
Sedlak, P. Narute, and T. Smithgall, et al., manuscript in preparation]. These prior studies were 
conducted with two laboratory strains of HIV-1, SF2 and NL4-3, once again raising the question 
of the broader applicability of these compounds against the many allelic variants of HIV-1 and 
Nef. Therefore, we first investigated the effect of the DFP analogs on primary Nef-mediated Hck 
activation and then evaluated the effect of DFP and PPD-B9 on replication of HIV-1 NL4-3 Nef 
chimeras that express each primary Nef protein.  
In the present study, we describe the evaluation of the broad specificity of these novel 
inhibitors of Nef function against HIV-1 replication. First, we first evaluated the activity of 4-
amino-substituted DFPs against primary Nef -mediated Hck activation using an in vitro kinase 
assay. Next, we successfully developed chimeric HIV-1NL4-3 expressing each individual primary 
Nef protein and then evaluated the antiretroviral activity of these novel inhibitors in cell culture. 
Active analogs of DFP identified in our previous work potently inhibited primary Nef-mediated 
Hck activation in vitro as well as replication of all of the HIV-1 Nef chimeras.  Similarly, PPD-
B9 also broadly inhibited HIV-1 replication in cell culture. These results validate the Nef-Hck 
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signaling axis as a viable target for development of broad-based inhibitors as a new approach to 
anti-retroviral therapeutics. 
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4.3 MATERIALS AND METHODS 
Cell lines and antibodies 
Human 293T cells were obtained from the ATCC and grown in Dulbecco’s Modified Eagle’s 
Medium/high glucose (Invitrogen) supplemented with 10% fetal bovine serum.  U87MG-CD4
+
/ 
CXCR4
+
, MT2 and CEM-T4 cells were obtained from the NIH AIDS Research and Reference 
Reagent Program.  U87MG-CD4
+
/CXCR4
+
 cells were grown in Dulbecco’s Modified Eagle’s 
Medium/high glucose supplemented with 25 mM HEPES, pH 7.4, 10% fetal bovine serum, 
G418 (400 µg/ml) and puromycin (0.5 µg/ml); G418 and puromycin are required to maintain 
expression of ectopically expressed CD4 and CXCR4 in this cell line.  MT2 and CEM-T4 cells 
were grown in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal bovine serum and 
2 mM L-glutamine. 
 Antibodies used in this study were obtained from the NIH AIDS Research and Reference 
Reagent Program (Nef, 2949; p24, 4121), Santa Cruz Biotechnology (Hck, sc-72; Lyn, sc-15; 
Fyn, sc-16; Lck, sc-13; c-Src, sc-18; Fgr, sc-17; pan-specific SFK, sc-5266), Abcam (Yes, 
Ab13954), Invitrogen (pY418, 44660G), and Millipore (actin, MAB 1501). 
 
In vitro kinase assay 
Nef-mediated activation of Hck tyrosine kinase activity was assayed using the Z’-Lyte method 
with the Tyr2 peptide substrate (Invitrogen/Life Technologies).  The principle of this FRET-
based assay is described in detail elsewhere (63,256) and in Figure 3.1. The assay conditions are 
described in Chapter 3.  
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HIV-1 Nef chimera construction and viral replication assay 
To generate the HIV-1 Nef chimeras, unique Cla I restriction sites flanking the Nef ORF were 
introduced into pUC18 carrying the complete HIV-1 NL4-3 proviral DNA sequence (pUC18-
NL4-3) (63,209). The coding sequences for the primary Nef genes as well as Nef-SF2 were 
PCR-amplified with Cla I linkers and used to replace the NL4-3 Nef sequence in pUC18-NL4-3.   
Control and chimeric viruses were generated by transfection of 293T cells, followed by 
amplification of the viral supernatants in the T cell line, MT2. To evaluate the infectivity, MT2 
cells were infected with 500pg/ml of each chimeric virus for 4 days in 6-well plate and imaged 
on a microscope (Nikon). HIV-1 replication was determined in cell culture supernatants using 
p24 ELISA. 
For HIV-1 replication assays, U87MG-CD4
+
/CXCR4
+
 and CEM-T4 cells were incubated 
overnight in the absence or presence of the DFP analogs or PPD-B9 in a final concentration of 
0.1% DMSO as carrier solvent.  U87MG-CD4
+
/CXCR4
+
 cells were then infected with 200 pg 
p24/ml of each chimeric virus for 5 d while CEM-T4 cells were infected with 62.5 pg p24/ml of 
each chimeric virus for 10 d in 96-well plates. HIV‐1 levels in the culture supernatants were then 
determined by p24 ELISA as described (63). 
 
Activation of endogenous SFKs by HIV-1 Nef chimeras 
CEM-T4 cells (1 x 10
5 
per T25 flask) were infected with 50 pg p24 equivalents/ml of wild-type 
HIV-1 NL4-3, a Nef-defective mutant (∆Nef), or the indicated Nef chimeras in a final culture 
volume of 10 ml in the absence or presence of 3 µM DFP-4A, DFP-4AP, DFP-4AB, or 1 µM 
PPD-B9 or the carrier solvent (DMSO) alone as a control (Con). The infected cells were lysed 
eight days later in RIPA buffer and SFK proteins were immunoprecipitated with a pan-specific 
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antibody against SFK and protein-G sepharose beads as described elsewhere (36,45). SFK 
activation was assessed by immunoblotting each immunoprecipitate with a phosphospecific 
antibody against the activation loop phosphotyrosine residue common to all Src family members 
(pY418; (232)).  Control blots were performed on cell lysates for HIV-1 Gag proteins (p55, p40, 
and p24), Nef, as well as actin as a loading control. 
 
Src-family kinase expression profiling  
CEM-T4 cells were lysed in RIPA buffer (202) and SFK protein levels were assessed by 
immunoblotting with antibodies specific for the individual Src family members. 
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4.4 RESULTS AND DISCUSSION 
4.4.1 Small molecule inhibitors of Nef-induced Hck activation are broadly effective 
against Hck activation by primary Nef proteins 
Recently we described a screening assay for small molecule inhibitors of Nef-dependent Hck 
activation in vitro (63). Using this assay, our laboratory identified a series of 4-amino substituted 
DFPs and PPD-B9 as potent inhibitors of both Nef-SF2-mediated Hck activation and Nef-
dependent HIV-1 replication.  Because these compounds represent potential leads for Nef-
directed HIV-1/AIDS therapeutics, we next examined whether these compounds inhibit Hck 
following activation by each of the recombinant primary Nef proteins using Z’-Lyte kinase 
assay.  As shown in Figure 23, both the 4-aminopropanol and 4-aminobutanol derivatives of DFP 
inhibited primary Nef-induced Hck activation by more than 50% at 10 µM.  Remarkably, the 
inhibitory action of both compounds was more pronounced with the primary Nef proteins than 
with Nef-SF2, the laboratory allele originally used to develop the screen.  In contrast, the 
unsubstituted 4-amino DFP pharmacophore was without effect, consistent with our previous 
results (63).  These results demonstrate that 4-amino substituted derivatives of DFP are broadly 
active against the Hck: Nef complex independent of the Nef isolate used.   
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Figure 23. Diphenylfuropyrimidine (DFP) analogs are broadly active against primary Nef-
mediated Hck activation. 
 
A) Structures of 4-amino DFP (DFP-4A) and the corresponding 4-aminopropanol (DFP-4AP) 
and 4-aminobutanol (DFP-4AB) analogs. B) Recombinant downregulated Hck [Hck-YEEI; 
(63,256,257)] activity was determined either alone or in the presence of the indicated Nef 
proteins as described in the text.  Reactions were run in the presence of 10 µM concentrations of 
DFP-4A, DFP-4AP, DFP-4AB, or the DMSO carrier solvent as negative control.  Results are 
expressed as the mean percent of maximum substrate phosphorylation ± S.D.; this experiment 
was repeated twice with comparable results.  
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In addition to 4-amino substituted diphenylfuranopyrimidines (DFPs), our lab has 
discovered a substituted diphenylpyrazolyldiazene (PPD-B9) in a high-throughput screening 
campaign for inhibitors of Nef-mediated Hck activation. This compound also blocks Nef-
dependent Hck activation as well as HIV-1 replication with submicromolar potency. Moreover, 
structural and computational studies using SPR and Autodock Vina respectively, suggest that 
PPD-B9 directly binds to two sites on the Nef surface. The binding of PPD-B9 to one site may 
induce conformational changes in Nef for high affinity binding of PPD-B9 to the second site, 
which is localized by the docking studies to the Nef dimer interface.  In contrast to the DFP 
compounds, PPD-B9 appears to represent a direct inhibitor of Nef activity (L. Emert-Sedlak, P. 
Narute, T. Smithgall, et al., manuscript in preparation). Since PPD-B9 was discovered using the 
same screening approach used for DFPs, we decided to evaluate its broad specificity against 
chimeric HIV-1 replication. 
 
4.4.2 Generation of chimeric HIV-1 and evaluation of replication and pathogenicity in 
MT2 cells 
In order to evaluate the broad specificity of recently discovered DFP compounds, we generated 
HIV-1NL43 chimeras expressing Nef alleles from all of the major clades. We first characterized 
the infectivity of each chimeric Nef virus in MT2 cells. As shown in Figure 24A, all of the HIV-
1NL43 Nef chimeras replicated as efficiently as wild-type HIV-1NL43 in MT2 cells where HIV-1 
replication is Nef-independent. Furthermore, as shown in Figure 24B, each chimeric form of 
HIV-1 produced Nef as well as other viral proteins, as detected by immunoblotting. Additionally 
we evaluated the cytopathic effect of these viruses in MT2 cells.  As shown in Figure 25, all of 
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the chimeric viruses produced cytopathic effects similar to wild type HIV-1 in MT2 cells. 
Overall, these results strongly indicate that all chimeric viruses are as infectious and replication-
competent as wild type HIV-1 NL43. 
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Figure 24. Replication of HIV-1 Nef chimeras in MT2 cells.  
A) MT2 cells (1 x 10
4 
per well of a 96-well plate) were infected with 500 pg p24 equivalents/ml 
of wild-type HIV-1 NL4-3, a Nef-defective mutant (∆Nef), or the indicated Nef chimeras in a 
final culture volume of 200 µl. HIV p24 levels were determined by ELISA 4 days later.  Data are 
presented as percent of p24 release observed relative to the HIV-1 NL4-3 control ± S.D.  B) 
U87MG-CD4
+
CXCR4
+
 cells (1 x 10
5
 per T-12.5 flask) were infected with 500 pg p24 
equivalents/ml of the same panel of viruses as in part A.  Viral Nef and Gag protein expression 
was verified by immunoblotting lysates of infected cells 4 days later.  Lysates from uninfected 
cells are included as a negative control (MT2; far left lane). 
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HIV-1 Δ Nef
HIV-1 NL43 WT
HIV-1 Nef SF2
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HIV-1 Nef A1 HIV-1 Nef A2
HIV-1 Nef B HIV-1 Nef C HIV-1 Nef F1 HIV-1 Nef F2
HIV-1 Nef G HIV-1 Nef H HIV-1 Nef J HIV-1 Nef K
 
Figure 25. HIV-1 Nef chimeras are as infectious and cytopathic as wild-type HIV-1 NL43. 
MT2 cells (1 x 10
5 
cells in T 12.5 flask) were infected with 500 pg/ml of the viral strain and 
incubated at 37 °C for 4 days and observed for the cytopathic effect of viral infection.  Note that 
syncytia formation by chimeric HIV-1 expressing the primary Nef proteins is very similar to that 
observed with wild-type HIV-1 NL43.  Red arrows indicate the presence of syncytia in each of 
the infected cultures. 
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4.4.3 HIV-1 replication is Nef-dependent in U87MG and CEM-T4 cells 
Previous work from our group and others has established that Nef expression is essential for 
optimal replication of HIV-1 in the astroglioma cell line U87MG which has been engineered to 
express CD4 and the co-receptor CXCR4 and in the T-cell line, CEM-T4 (48,63,196).  
Replication of HIV-1 strain NL4-3 is potently inhibited by 4-amino substituted DFP compounds 
in the U87MG model system, and this inhibitory effect is dependent upon the expression of Nef 
(63).  In order to investigate the broader utility of the DFP compounds against M-group HIV-1 
isolates, we first needed to demonstrate functional enhancement of HIV-1 replication by each of 
our primary nef alleles in these cell lines.  We then evaluated the ability of each primary nef 
allele to support HIV-1 replication in U87MG- CD4
+
/CXCR4
+
 cells.  As observed previously, 
Nef-defective HIV-1 replicated very poorly in this cell line (Figure 26A). However, replication 
of each of the Nef chimeras was indistinguishable from wild-type HIV-1 NL4-3, demonstrating 
that these Nef proteins function to support HIV replication.  Immunoblots demonstrate that each 
Nef variant is expressed in infected cells, along with the major capsid proteins (Figure 26B).  
Similarly, replication of Nef-defective HIV-1 replicated to only 10% of wild-type levels in 
CEM-T4 cells, and this replication defect was completely rescued by cis-complementation with 
all of the primary Nef alleles tested (Figure 27A).  Immunoblotting verified Nef expression in 
CEM-T4 cells infected with wild-type HIV-1 and each of the chimeras, as well as capsid proteins 
(Figure 27B).  These results demonstrate that HIV-1 replication is Nef-dependent in both the 
U87MG-CD4
+
/CXCR4
+ 
and CEM-T4 cell lines, providing an important new tool to interrogate 
the broad efficacy of small molecule inhibitors of Nef function on M-group HIV-1 replication. 
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Figure 26. Replication of HIV-1 Nef chimeras in U87MG-CD4
+
/CXCR4
+
 cells. 
A) U87MG- CD4
+
/CXCR4
+
 cells (2 x 10
4 
per well of a 96-well plate) were infected with 200 pg 
p24 equivalents/ml of wild-type HIV-1 NL4-3, a Nef-defective mutant (∆Nef), or the indicated 
Nef chimeras in a final culture volume of 200 µl. HIV p24 levels were determined by ELISA 5 
days later.  Data are presented as percent of p24 release observed relative to the HIV-1 NL4-3 
control ± S.D.  B) U87MG-CD4
+
CXCR4
+
 cells (1 x 10
5
 per well of a 6-well plate) were infected 
with 1 ng p24 equivalents/ml of the same panel of viruses as in part A.  Viral Nef and Gag 
protein expression was verified by immunoblotting lysates of infected cells 4 days later.  Lysates 
from uninfected cells are included as a negative control (U87MG; far left lane). 
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Figure 27. Replication of HIV-1 Nef chimeras in CEM-T4 cells. 
A) CEM-T4 cells (1 x 10
4 
per well of a 96-well plate) were infected with 62.5 pg p24 
equivalents/ml of wild-type HIV-1 NL4-3, a Nef-defective mutant (∆Nef), or the indicated Nef 
chimeras in a final culture volume of 200 µl. HIV p24 levels were determined by ELISA 10 days 
later. Data are presented as percent of p24 release observed relative to the NL4-3 control ± S.D.  
B) CEM-T4 cells (5 x 10
5
 per well of a 6-well plate) were infected with 1 ng p24 equivalent/ml 
of the same panel of viruses as in part A.  Viral Nef and gag protein expression was verified by 
immunoblotting lysates of infected cells 6 days later.  Lysates from uninfected cells are included 
as a negative control (CEM-T4; far left lane). 
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4.4.4 Small molecule inhibitors of Nef-induced Hck activation are broadly active 
inhibitors of HIV-1 Nef chimera replication 
As described in the preceding sections, 4-amino substituted DFP analogs are potent inhibitors of 
both Nef-dependent SFK activation and HIV replication (63).  Two DFP derivatives, DFP-4-AP 
and DFP-4-AB, showed potent inhibition of Hck activation by all of the recombinant M-group 
Nef proteins tested (Figure 23), suggesting that they may inhibit replication of the HIV-1 
chimeras expressing each of these primary Nef alleles as well.  To test this possibility, we 
infected both U87MG-CD4
+
/CXCR4
+
 and CEM-T4 cells with wild-type HIV-1 NL4-3, the Nef-
defective mutant and the 10 Nef chimeras in the absence or presence of DFP-4-AP or DFP-4-
AB.  As shown in Figure 28, both 4-amino DFP analogs inhibited replication of wild-type HIV-
1, as well as all of the Nef chimeras, by more than 75% at a concentration of 3 µM in both cell 
lines.  In contrast, the compounds had no impact on the replication of Nef-defective HIV-1, 
demonstrating that antiretroviral activity of the DFP analogs requires the expression of Nef.  As 
with the in vitro kinase assays, the unsubstituted 4-amino DFP pharmacophore was completely 
inactive, consistent with our original observations (63).   
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Figure 28. Inhibition of HIV-1 Nef chimeras by 4-amino DFP analogs. 
U87MG-CD4
+
/CXCR4
+
 cells (upper panel) and CEM-T4 cells (lower panel) were infected with 
wild-type HIV-1 NL4-3, a Nef-defective mutant (∆Nef), or the indicated Nef chimeras as 
described in the legends to Figures 26 and 27.  DFP-4A, DFP-4AP, or DFP-4AB were added to 
the cultures to a final concentration of 3 µM, and viral replication was determined by p24 ELISA 
5 days (U87MG) or 10 days (CEM-T4) later.  Data are expressed as the mean percent of HIV-1 
replication observed in control cultures incubated with the carrier solvent (0.1 % DMSO) ± S.D. 
(n=6). 
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To obtain more insight into the mechanism by which these compounds inhibited the HIV-
1 replication in CEM-T4 cells, we investigated the effect of HIV-1 infection on endogenous SFK 
activation in CEM-T4 T cells, as well as the impact of the DFP-based inhibitors on HIV-
mediated kinase activation.  For these studies, CEM-T4 cells were infected with wild-type HIV 
NL4-3, the Nef-defective mutant, as well as each of the 11 Nef chimeras.  Infected cells were 
lysed and SFK activity was monitored with a phosphospecific antibody that recognizes the 
phosphotyrosine residue in the activation loop of active SFKs (pY416). As shown in Figure 29 
B, HIV infection resulted in a Nef-dependent increase in endogenous Src-family kinase 
activation in every case.  Immunoblots with SFK isoform-specific antibodies revealed that CEM-
T4 cells express the direct Nef targets c-Src and Hck (Figure 29 A), which are most likely the 
SFKs activated by Nef in this system.  Furthermore, when cells were treated with DFP-4AB or 
DFP-4AP, both of which block Nef-dependent HIV-1 replication (Figure 28), SFK activation 
was completely inhibited.  In contrast, the inactive DFP analog, DFP-4A, had no effect on kinase 
activity.   
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Figure 29. Inhibition of HIV-1 Nef chimera-mediated activation of endogenous SFKs in 
CEM-T4 cells by 4-amino DFP analogs. 
A) CEM-T4 cells were lysed in RIPA buffer (202) and SFK protein levels were assessed by 
immunoblotting with antibodies specific for the individual Src family members shown.  Lysates 
were also blotted with actin antibodies as a loading control. This expression profile shows that 
the CEM-T4 lymphoblasts express Hck, Lyn, c-Src, Lck, Fyn and Yes.  B) CEM-T4 cells were 
infected with wild-type HIV-1 NL4-3 (WT), a Nef-defective mutant (∆Nef), or the indicated Nef 
chimeras in the absence or presence of 3 µM DFP-4A, DFP-4AP, DFP-4AB, or the carrier 
solvent (DMSO) alone as a control (Con).  The infected cells were lysed and SFK proteins were 
immunoprecipitated with a pan-specific antibody against SFK and protein G-sepharose beads. 
SFK activation was assessed by immunoblotting with a phosphospecific antibody against the 
activation loop phosphotyrosine residue common to all Src family members (pY418).  Control 
blots were performed on cell lysates for HIV-1 Gag proteins (p55, p40, and p24), Nef, as well as 
actin as a loading control.  Results from uninfected cells are shown in the far right lane (no virus 
control).  This experiment was repeated twice with comparable results. 
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 Next, we evaluated the effect of PPD-B9 on replication of HIV-1 Nef chimeras in CEM-
T4 cells. As shown in Figure 30, PPD-B9 inhibited replication of wild-type HIV-1, as well as all 
of the Nef chimeras, in a dose-dependent manner in CEM T4 cells compared to the DMSO 
control. PPD-B9 demonstrated more potent activity than DFPs; it inhibited HIV-1 replication by 
more than 75% at a concentration of 1 µM.   Similar to DFPs, PPD-B9 also had no impact on the 
replication of Nef-defective HIV-1, demonstrating that antiretroviral activity requires the 
expression of Nef. Furthermore, we evaluated the impact of the PPD-B9 on HIV-mediated 
endogenous SFK activation in CEM T4 cells. As shown in Figure 31, HIV infection resulted in a 
Nef-dependent increase in endogenous Src-family kinase activation in every case. When these 
cells were treated with PPD-B9, there was strong inhibition of endogenous SFK activation. This 
result suggests that PPD-B9 also inhibits HIV-1 replication by inhibiting Nef-mediated SFK 
activation. These data provide important new evidence that HIV-1 infection results in sustained 
SFK activation in a Nef-dependent manner.  This function is shared by nef alleles derived from 
all major HIV-1 clades in the context of HIV-1 replication.  Furthermore, this pathway is 
sensitive to the DFP compounds as well as PPD-B9, strongly supporting inhibition of this 
pathway as their primary mechanism of action. These results support the conclusion that 
therapeutic targeting of Nef-dependent SFK activation might represent a broadly useful strategy 
against HIV-1 replication. 
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Figure 30. Inhibition of HIV-1 Nef chimeras by PPD-B9. 
CEM-T4 cells were infected with wild-type HIV-1 NL4-3, a Nef-defective mutant (∆Nef), or the 
indicated Nef chimeras as described in the legends to Figures 26 and 27.  The direct Nef 
antagonist PPD-B9 was added to the cultures to final concentrations of 0.3 and 1.0 µM, and viral 
replication was determined by p24 ELISA 10 days later.  Data are expressed as the mean percent 
of HIV-1 replication observed in control cultures incubated with the carrier solvent (0.1 % 
DMSO) ± S.D. (n=6). 
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Figure 31. Inhibition of HIV-1 Nef chimera-mediated activation of endogenous SFKs in 
CEM-T4 cells by PPD-B9. 
CEM-T4 cells (1 x 10
5 
per T25 flask) were infected with 50 pg p24 equivalents/ml of wild-type 
HIV-1 NL4-3, a Nef-defective mutant (∆Nef), or the indicated Nef chimeras in a final culture 
volume of 10 ml in the absence or presence of 1 µM PPD-B9 or the carrier solvent (DMSO) 
alone as a control (Con). The infected cells were lysed and Src-family kinase proteins were 
immunoprecipitated with a pan-specific antibody and G-sepharose beads. The SFK activation 
state was assessed by immunoblotting each immunoprecipitate with a phosphospecific antibody 
against the activation loop phosphotyrosine residue common to all Src-family members (pY418). 
Control blots were performed on cell lysates for HIV-1 Gag proteins (p55, p40, and p24), Nef, as 
well as actin as a loading control.  Results from uninfected cells are shown in the far right lane 
(No virus control). This experiment was repeated twice with comparable results. 
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4.5 SIGNIFICANCE AND CONCLUSION 
In spite of more than 30 years of research in the field of HIV-1 since the first report of AIDS, a 
vaccine is not available. The current therapeutic regimen used is ineffective and contraindicated 
in some cases. HIV-1 eventually develops resistance against current anti-HIV drugs due to error- 
prone replication of the genome. Thus, a strong need exists for the development of new drugs to 
inhibit critical steps in HIV-1 pathogenesis. HIV-1 Nef is an essential virulence factor for 
development of AIDS, and has long been considered as a viable drug target. Here we 
demonstrate that 4-amino substituted DFP analogs as well as PPD-B9 exhibit a broad spectrum 
of activity against Nef:Hck complexes in cells.  Importantly, both the DFP-based compounds and 
PPD-B9 showed equipotent inhibition of Nef-dependent HIV-1 replication using a panel of HIV-
1 Nef chimeras representative of all major HIV-1 clades.  Inhibition of viral replication 
correlated with inhibition of Nef-dependent activation of endogenous SFKs in the infected cells. 
These observations strongly support the development of new antiretroviral agents that target the 
interaction of this key HIV-1 virulence factor with SFKs and other host cell signaling proteins.   
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5.0  OVERALL DISCUSSION 
5.1 SUMMARY OF MAJOR FINDINGS 
My PhD research involves evaluation of HIV-1 Nef interactions with Src Family Kinases (SFKs) 
for the purpose of therapeutic intervention.  In this project, we explored whether SFK activation 
is a conserved property of nef alleles from a wide range of primary HIV-1 isolates.  
Representative Nef proteins from the HIV-1 major subgroups A1, A2, B, C, F1, F2, G, H, J and 
K strongly activated Hck and Lyn as well as c-Src to a lesser extent, demonstrating for the first 
time that SFK activation is a highly conserved property of HIV-1 Nef isolates. To evaluate this 
functional property of the M-group HIV-1 Nef clade set, we first evaluated the binding of 
purified recombinant Nef proteins with Hck SH3 domain. All primary Nef proteins showed 
robust binding to the wild-type Hck SH3 domain, while no binding was observed with the Hck 
SH3 W93A mutant or with GST alone consistent with previous reports with laboratory Nef 
alleles. Moreover, using SPR, we showed that similar to Nef-SF2, most of the primary Nef 
proteins have high affinity for Hck SH3 domain. We next showed that all primary Nef proteins 
can activate recombinant Hck in the FRET-based, Z’-Lyte kinase assay. In addition to this, using 
our well established yeast-based kinase assay, we showed that all of the primary Nef alleles 
strongly activated Hck, Lyn and c-Src to a lesser extent among all SFKs expressed HIV-1 target 
cells. None of the nef alleles had measurable effects on other SFKs including Lck, Fyn and Fgr, 
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consistent with previous reports from our group with common B-clade laboratory alleles. 
Furthermore, we also showed that Nef-mediated Hck activation is highly conserved in nef alleles 
derived from AIDS patients. 
 As detailed in the Introduction, Nef induces a unique active Hck conformation by 
displacing SH2-kinase linker interaction with the SH3 domain without affecting SH2-tail 
interaction. We believe that this unique conformation might drive differential signaling pathways 
in HIV-1 infected cells and thus allow discovery of selective small molecule inhibitors of Nef-
mediated Hck activation without affecting physiological Hck signaling. This hypothesis needs to 
be evaluated in detail to get an idea about specific signaling pathways involved in Nef-Hck 
mediated enhancement of HIV-1 pathogenesis. This can be evaluated by comparing global 
protein expression, phosphorylation, and gene expression profiles from cells (especially U87MG, 
U937 and CEM-T4 cells) expressing an active form of Hck (Hck-YF) versus co-expression of 
Nef and Hck. Once candidate signaling pathways are identified, these can be validated using 
specific promoter-reporter assay system.  
 Moreover, we also observed that Nef-mediated activation of Lyn leads to robust 
phosphorylation of the Nef protein itself in the yeast screen, which is less evident in case of Hck. 
This difference could be due to a saturation effect caused by less stringent substrate specificity of 
Hck in yeast compared to Lyn. Interestingly, the tyrosine phosphorylation of Nef by these SFKs 
raises the possibility that this may influence the interaction of Nef with other signaling molecules 
containing SH2 domains. Bioinformatics studies have identified 115 proteins with SH2 domains 
encoded by human genome (162). Whether or not tyrosine phosphorylation of Nef drives its 
interaction with SH2-containing targets could be addressed by affinity screening of tyrosine 
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phosphorylated Nef with a phage-display library containing a collection of all human SH2 
domains as described recently for screening of Nef with human SH3 domains (130).  
 In the present study we have not seen direct interaction of Nef with the T cell specific 
SFK, Lck, despite the fact that several previous studies reported the physical and functional 
interaction of Nef with Lck (14,19,53,256,275). The yeast system used for these studies directly 
evaluates the interaction of HIV-1 Nef with SFKs (See Chapter 3) and therefore clearly rule out 
the direct interaction of Nef with Lck. In contrast, these other studies have used mammalian cell 
systems, raising the possibility that adaptor proteins are also involved in Nef-Lck interaction. 
Moreover, Collette et al. showed that both the PxxP motif as well as tyrosine phosphorylation of 
Nef are necessary for this interaction (53). As mentioned before, tyrosine phosphorylation of Nef 
by other SFKs might affect the interaction of Nef with other kinases. Similar to Lck, we have not 
seen a measurable effect of Nef on Fyn, another SFK involved in TCR signaling. As detailed in 
Chapter 3, studies have shown that Nef interacts with a Fyn isoform expressed in T cells and this 
interaction is stabilized by TCR CD3 ζ chain. The functional consequences of this multi-protein 
complex (Nef-Fyn- CD3 ζ chain) should be further evaluated using yeast-based system.   
Despite of development of HAART therapy, it is difficult to completely cure individuals 
suffering with HIV-1 as well as to prevent new infection which underscores the strong need for 
new drugs.  Nef represents an important potential drug target because of its important role in 
HIV-1 pathogenesis and interactions with host cell signaling molecules. Recently, our lab 
identified several unique classes of small molecule inhibitors of Nef-mediated Hck activation 
and HIV-1 replication by screening a chemical library of more than 220,000 compounds. Here I 
extended these findings by showing that representatives of two compound classes, the DFP 
analogs and PPD-B9, also showed efficacy against all primary Nef proteins in HIV-1 replication 
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assays. To accomplish this goal, I first generated a series of HIV-1 NL4-3 chimeras expressing 
the representative nef alleles from each of the major clades by substitution of the endogenous 
Nef ORF in the wild-type NL4-3 provirus. These HIV-1 Nef chimeras replicated equally in 
MT2, U87MG CD4+/CXCR4+ and CEM-T4 cell lines. The DFP analogs inhibited replication of 
wild-type HIV-1, as well as all of the Nef- chimeras, by more than 75% at 3 µM in U87MG 
CD4+/CXCR4+ and CEM-T4 cell lines. Similar to DFPs, PPD-B9 also broadly inhibited 
replication of wild-type as well as each of Nef chimeras. PPD-B9 demonstrated even more 
potent activity than DFPs, inhibiting HIV-1 replication by more than 75% at a cellular 
concentration of just 1 µM. We next showed that HIV-1 infection results in activation of 
endogenous SFKs in CEM T4 cells in Nef-dependent manner. In addition to this, we also 
showed that both DFPs and PPD-B9 inhibited HIV-1 replication by blocking HIV-1-mediated 
activation of endogenous SFKS.   These results support the conclusion that therapeutic targeting 
of Nef-dependent Src-family kinase activation may represent a broadly useful strategy against 
HIV-1. 
The discovery of broadly active Nef-directed antiretroviral compounds such as the DFPs 
and PPD-B9 has great public health significance in terms of salvage therapy for people infected 
with current drug resistant HIV-1. Unlike other drugs which directly target the essential viral 
enzymes such as RT and protease, we have targeted a virus-host cell protein interaction which 
inherently reduces the chances of development of drug resistance. HIV-1 Nef not only enhances 
HIV-1 replication but also disturbs the host immune system. We expect that treatment with Nef-
directed drugs will blunt HIV-1 pathogenesis, resulting in a response similar to LNTPs or 
macaques infected with Nef-defective viruses. My work strongly suggests that these compounds 
inhibit HIV-1 replication by blocking Nef-mediated SFK activation, further supporting the role 
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of this interaction in AIDS pathogenesis. These compounds should be further evaluated in terms 
of other Nef-mediated immune defects including downregulation of MHC class I molecules, 
chemokine co-receptors as well as other functions as described in next section. We expect that 
global blockade of Nef function by these inhibitors will be highly beneficial if added to HAART 
in terms of a better immune response to HIV-1 infection as well as reducing the risk of drug 
resistance to HAART.  
 
Model of Nef-SFK signaling in HIV-1 pathogenesis 
As described in detail in the Introduction, Nef is versatile adaptor protein that interacts with 
diverse cellular proteins. In particular, the PxxP motif of Nef is involved in binding and 
activation of SFKs. Saksela et al. were the first to demonstrate the importance of the PxxP motif 
in enhancement of HIV-1 replication in PBMCs (226). Among all cellular Nef-interacting 
partners with SH3 domains, Hck remains as the highest affinity binding partner for Nef 
(155,226). 
 In terms of downstream signaling pathways for Nef-SFK complexes, Nef expression in 
murine and human macrophages enhanced AP-1 DNA binding activity through activation of 
MAPK signaling pathway in PxxP-dependent manner. This activation of MAPK pathway was 
further associated with increased levels of c-fos and increased expression of the AP-1 responsive 
gene, tissue inhibitor of metalloproteinase-1 (TIMP-1) (23). This Nef-mediated activation of the 
MAPK pathway was blocked by expression of a dominant negative form of Hck, underscoring 
the importance of Nef-mediated Hck activation (23). Several studies have shown a role for the 
AP-1 signaling pathway in the induction of pro-inflammatory cytokines as well as enhanced 
expression from the HIV-1 LTR (112,166,262,284,285).  Moreover, Nef expression in human 
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macrophages promotes survival through activation of STAT3 (34), although a role for Hck in 
this pathway has not been established. The Erk MAPK pathway is also activated by Nef in T 
cells in a Lck-dependent manner (275), although my work suggests that Lck must serve an 
indirect role as it does not interact with Nef directly. Moreover, Nef-mediated enhancement of 
HIV-1 transcription in T cells is also dependent on Lck activity (275,276). Finally, Nef 
expression in T cells causes transcriptional downregulation of the HIV-1 genome through 
induction of inhibitory factors like IL-2, IL-16 and the transcriptional regulator, YY-1 (241). 
 Nef has also been implicated in the high proliferation rate and loss of differentiation 
markers in podocytes in a murine model of HIV-1 associated nephropathy (HIVAN) 
(102,120,129).  This renal phenotype was abolished by expressing the PxxP mutant of Nef but 
not by Hck knock out (104). Biochemical studies revealed that Nef activates c-Src and the 
STAT3 transcription factor in this system. Moreover, this study also showed that Nef activates 
the Ras-Raf-MAPK signaling cascade. This study revealed that the STAT3 and MAPK pathways 
are both activated in podocytes from the murine model of HIVAN as well as HIVAN patients. 
This effect is reversed by expression of dominant negative form of c-Src (110).  
In conclusion, Nef-mediated SFK activation leads to activation of STAT3, AP-1, and 
MAPK signaling downstream which is ultimately responsible for enhancement of HIV-1 
replication. Our study demonstrated discovery broadly active Nef inhibitors DFPs and PPD-B9 
which inhibited HIV-1 replication in two different cell lines. Furthermore, we also demonstrated 
that these inhibitors block the HIV-1 mediated activation of endogenous SFKs in a Nef-
dependent manner. These results suggest that both compounds inhibit Nef-proximal signaling 
pathways i.e. Nef-mediated SFK activation, which in turn leads to the activation of multiple 
signlaing pathways downstream that contribute to HIV-1 pathogenesis. This hypothesis needs to 
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be investigated in more detail by evaluating impact of these compounds on the downstream 
signaling pathways described above. These experiments will enable us to evaluate differential 
effects of DFPs versus PPD-B9 on Nef signaling. As described in Chapter 4, in addition to 
inhibiting Nef-mediated Hck activation, PPD-B9 is also a potential direct inhibitor of Nef 
oligomerization. Because it interacts directly with Nef, we predict that PPD-B9 will show 
broader specificity against Nef-mediated activation of cell signaling pathways compared to 
DFPs. 
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5.2 FUTURE DIRECTIONS 
5.2.1 Evaluation of the activity of newly discovered Nef inhibitors in PBMCs  
The present study reported the discovery of broadly specific HIV-1 Nef inhibitors which 
inhibited HIV-1 replication in cell lines (U87MG and CEM-T4) where HIV-1 replication is Nef-
dependent. Similar to these continuous cell lines (U87MG and CEM-T4), others have reported 
that HIV-1 replication is Nef-dependent in peripheral blood mononuclear cells (PBMCs) as well 
as co-culture of T cells with macrophages or endothelial cells (46,178,236,245). This system 
may be closer to natural HIV-1 infection in the host where antigen presenting cells (APCs) have 
major role in activation of naïve T cells and enhancing HIV-1 replication. Several studies have 
shown the importance of nef gene in APC-mediated activation of T cells as well as enhancement 
of HIV-1 infection in CD4
+
 cells (250,251). Therefore, it will be important to evaluate the effect 
of DFPs and PPD-B9 on HIV-1 replication in this system. Moreover, the development of DFP- 
and PPD-B9-resistant HIV-1 mutants will help us to understand the impact of evolutionary 
mutations in Nef on SFK signaling. 
5.2.2 Evaluation of the efficacy of Nef inhibitors in animal model 
In the present study we have shown that both DFP analogs and PPD-B9 are broadly active 
against HIV-1 expressing Nef from all major clades of HIV-1. This makes them potential 
candidates for therapeutic intervention for AIDS patients. To move forward in this direction, we 
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need to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of these compounds in 
order to determine plasma half-life, dose as well as toxicity in a suitable animal model. The 
chimpanzee, cats (FIV) and macaques (SIV) are the closest animal models for AIDS in humans 
(79). In addition to these expensive animal models, Hanna et al. described HIV-1 and HIV-1 
Nef-transgenic mouse model characterized by AIDS-like disease development (101,102). In 
addition to PK/PD study, these transgenic mice are suitable to evaluate the efficacy of these 
novel inhibitors in vivo. The efficacy of these compounds should be evaluated for interference 
with progression of AIDS-like disease by blocking Nef function before moving forward to non-
human primate (SIV) models.  
As mentioned in the Introduction, the present therapeutic regimen for AIDS is HAART 
which is composed of a combination of three or more drugs targeting different stages of the HIV-
1 life cycle. HIV-1 develops drug-resistance due to its rapid replication rate (10
10
 virions 
produced per day) and high mutation rate (3 x 10
−5
 per nucleotide base per cycle). Our results 
showed that DFPs and PPD-B9 inhibited HIV-1 replication by more than 75% at low micromolar 
concentrations by targeting host cell signaling. It would be interesting to evaluate the impact of 
addition of these inhibitors to HAART on development of drug resistance in the simian AIDS 
model. I expect that inhibition of HIV-1 replication by Nef inhibitors will help to overcome the 
development of drug resistance to HAART. Similarly, a live attenuated vaccine produced by 
deleting the nef gene from SIV was very promising in controlling simian AIDS. So it would be 
interesting to evaluate the effect of these Nef inhibitors as chemical adjuvants in development of 
vaccines for AIDS. 
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5.2.3 Insights towards mechanism of action 
The experiments presented in this study clearly indicate that DFPs and PPD-B9 inhibitors of Nef 
blocked HIV-1-mediated activation of endogenous SFKs as well as HIV-1 replication in a Nef-
dependent manner.  This observation leads to the new hypothesis that DFPs and PPD-B9-
mediated inhibition of endogenous SFKs causes inhibition of HIV-1 replication. One way to 
validate this hypothesis is to use anti-sense or small interfering RNA specific for Hck and/or c-
Src with the assay described in section 4.4.4. Additionally, one could express a constitutively 
active form of Hck and/or c-Src in HIV-1 target cells and evaluate the effect of these Nef 
inhibitors on HIV-1 replication. As Nef-SFK signaling has a major impact on signaling pathways 
in infected cells, the specific cell signaling pathways affected by these inhibitors is unknown. 
Several studies have shown that Nef expression results in secretion of cytokines by macrophages 
and activation of T cells (71,143,204,231,241,250,251)  as well as enhancement of transcription 
from the LTR promoter (10,184,241,277). Similarly, studies have reported that activation of 
SFKs (Hck in macrophages, Lck/Fyn in T cells) is involved in macrophage (252,292) and T cell 
activation (195). Based on this information, the Nef-mediated gene expression profiling in the 
absence and presence of these inhibitors, especially in U87MG and CEM-T4 cells where HIV 
replication is Nef-dependent, will help us to obtain insights into which signaling pathways are 
affected by these novel inhibitors of Nef.  Alternatively, a phosphoproteomics approach in a 
similar setting may reveal in broader terms the kinase pathways affected by these compounds. 
Finally, Swingler et al. (251) described an assay to evaluate the paracrine effects of 
macrophages on T cell chemotaxis and activation as well as enhancement on HIV-1 replication 
in T cells. Using a similar system, the paracrine effect of culture supernatants from macrophages 
expressing Nef (in the absence and presence of these inhibitors) could be evaluated by assessing 
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the activation of T cells, chemotaxis of T cells, HIV-1 replication and transcription from the 
LTR. The results from these experiments will give us a clearer idea about the impact of these 
compounds on macrophage-mediated enhancement of HIV-1 replication in T cells. 
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5.3 CLOSING REMARKS 
HIV-1, the human retrovirus responsible for AIDS, encodes several small “accessory factors” 
essential for viral growth and disease progression in infected individuals.  One of these factors, 
termed Nef, promotes viral infection of HIV target cells, enhances viral replication, and allows 
HIV-infected cells to escape recognition by the host immune system.  Nef works in part by 
binding to a variety of host cell signaling molecules and disrupting their regulation.  The focus of 
my dissertation is a group of Nef-interacting partner proteins known as Src-family kinases 
(SFKs), which we have previously shown to be activated by Nef proteins derived from 
laboratory strains of HIV-1. In this study, we demonstrate that Nef proteins derived from all of 
the major subtypes of HIV-1 responsible for the global pandemic specifically bind and activate 
the same subset of SFKs.  Moreover, we found that pharmacological inhibition of Nef-mediated 
SFK activation blocks the enhancement of HIV-1 replication supported by all of the Nef 
subtypes tested.  These results are significant because they establish for the first time that host 
cell SFK signaling is activated by Nef variants examined from all clades of HIV-1, and that 
inhibition of this pathway may represent a broadly useful strategy to combat HIV/AIDS. 
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